

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

# **BMJ Open**

### Prevalence of Tuberculosis and Human Immunodeficiency Virus in Zambian correctional facilities

Journal:BMJ OpenManuscript IDbmjopen-2021-052221Article Type:Original researchDate Submitted by the Author:14-Apr-2021Complete List of Authors:Kagujje, Mary; Center for Infectious Disease Research in Zambia, Tuberculosis department Hatwiinda, Sisa; Center for Infectious Disease Research in Zambia, Tuberculosis department Somwe, Paul; Center for Infectious Disease Research in Zambia, Strategic Information department Bwalya, Joel; Center for Infectious Disease Research in Zambia, Strategic Information department Bwalya, Joel; Center for Infectious Disease Research in Zambia, Strategic Information department Egambo, Tamala; Zambia Correctional Service Thornicroft, Moomba; Center for Infectious Disease Research in Zambia, Strategic Information department Bozzani, Fiammetta; London School of Hygiene and Tropical Medicine Faculty of Public Health and Policy Moorga, Clement; Center for Infectious Disease Research in Zambia
Article Type:Original researchDate Submitted by the Author:14-Apr-2021Complete List of Authors:Kagujje, Mary; Center for Infectious Disease Research in Zambia, Tuberculosis department Hatwiinda, Sisa; Center for Infectious Disease Research in Zambia, Tuberculosis department Somwe, Paul; Center for Infectious Disease Research in Zambia, Strategic Information department Bwalya, Joel; Center for Infectious Disease Research in Zambia, Strategic Information department Zgambo, Tamala; Zambia Correctional Service Thornicroft, Moomba; Center for Infectious Disease Research in Zambia Tuberculosis department Eozzani, Fiammetta; London School of Hygiene and Tropical Medicine Faculty of Public Health and Policy
Date Submitted by the Author:14-Apr-2021Complete List of Authors:Kagujje, Mary; Center for Infectious Disease Research in Zambia, Tuberculosis department Hatwiinda, Sisa; Center for Infectious Disease Research in Zambia, Tuberculosis department Somwe, Paul; Center for Infectious Disease Research in Zambia, Strategic Information department Bwalya, Joel; Center for Infectious Disease Research in Zambia, Strategic Information department Zgambo, Tamala; Zambia Correctional Service Thornicroft, Moomba; Center for Infectious Disease Research in Zambia Tuberculosis department Egambo, Tamala; Zambia Correctional Service Thornicroft, Moomba; Center for Infectious Disease Research in Zambia Tuberculosis department Bozzani, Fiammetta; London School of Hygiene and Tropical Medicine Faculty of Public Health and Policy
Author:14-Apr-2021Complete List of Authors:Kagujje, Mary; Center for Infectious Disease Research in Zambia, Tuberculosis department Hatwiinda, Sisa; Center for Infectious Disease Research in Zambia, Tuberculosis department Somwe, Paul; Center for Infectious Disease Research in Zambia, Strategic Information department Bwalya, Joel; Center for Infectious Disease Research in Zambia, Strategic Information department Zgambo, Tamala; Zambia Correctional Service Thornicroft, Moomba; Center for Infectious Disease Research in Zambia Tuberculosis department Egambo, Tamala; Zambia Correctional Service Thornicroft, Moomba; Center for Infectious Disease Research in Zambia Tuberculosis department Bozzani, Fiammetta; London School of Hygiene and Tropical Medicine Faculty of Public Health and Policy
Tuberculosis department Hatwiinda, Sisa; Center for Infectious Disease Research in Zambia, Tuberculosis department Somwe, Paul; Center for Infectious Disease Research in Zambia, Strategic Information department Bwalya, Joel; Center for Infectious Disease Research in Zambia, Strategic Information department Zgambo, Tamala; Zambia Correctional Service Thornicroft, Moomba; Center for Infectious Disease Research in Zambia Tuberculosis department Bozzani, Fiammetta; London School of Hygiene and Tropical Medicine Faculty of Public Health and Policy
Muyoyeta, Monde ; Center for Infectious Disease Research in Zambia
Keywords: Tuberculosis < INFECTIOUS DISEASES, HIV & AIDS < INFECTIOUS DISEASES, EPIDEMIOLOGY, PUBLIC HEALTH

SCHOLARONE<sup>™</sup> Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

review only

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

2	
3	
4	
5	
6	
6 7	
8	
9 10	
10	
11	
12	
13	
14	
15	
16	
12 13 14 15 16 17 18	
18	
19	
20	
23	
24	
25	
26	
26 27	
28	
29	
30	
31	
32	
2∠ 22	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
52 53	
54	
55	
56	
57	
58	
59	
60	

1	Prevalence of Tuberculosis and Human Immunodeficiency
2	Virus in Zambian correctional facilities
3	

- 4 Mary Kagujje (0000-0003-4818-6548)<sup>1</sup>, Sisa Hatwiinda<sup>1</sup>, Paul Somwe<sup>2</sup>, Joel Bwalya<sup>2</sup>, Tamala
- 5 Zgambo<sup>3</sup>, Moomba Thornicroft<sup>1</sup>, Fiammetta Bozzani<sup>4</sup>, Clement Nchimunya Moonga<sup>1</sup>, Monde
- 6 Muyoyeta<sup>1</sup>

8

9

12

13

15

17

19

- 7 Author affiliations
  - Tuberculosis department, Centre for Infectious Disease Research in Zambia, P.O. Box 34681
     Lusaka, Zambia 10101
- Strategic Information department, Centre for Infectious Disease Research in Zambia, P.O. Box
   34681 Lusaka, Zambia 10101
  - 3. Zambia Correctional Service, P.O. Box 80926 Kabwe, Zambia 10101
  - 4. London School of Hygiene and Tropical Medicine, Keppel Street London WCIE 7HT, United
- 14 Kingdom
  - 16 Correspondence to Mary Kagujje; <u>mkagujje@gmail.com</u>
  - 18 Key words: Correctional facilities, Tuberculosis, HIV, Zambia

# 21 ABSTRACT

**Objective:** To determine the prevalence of Tuberculosis (TB) and Human Immunodeficiency

23 virus (HIV) in Zambian correctional facilities.

24 Methods: Cross sectional study

**Setting:** 13 correctional facilities in 7 of the 10 provinces in Zambia.

26 Participants: All incarcerated individuals were eligible for TB and HIV screening and testing.

27 Of the total population of 9,699 individuals, 8,271 and 8,164 were screened for TB and HIV

- 28 respectively.
- Interventions: Mass and entry screening in correctional facilities was done between July 2018
   and February 2019.
- 31 Primary outcome measures: All forms of TB, bacteriologically confirmed TB, drug resistant
   32 TB, HIV

Results: Prevalence of all forms of TB and bacteriologically confirmed TB was 1598 per 100,000 population and 1056 per 100,000 population, respectively. Among those with bacteriologically confirmed TB, 4.6% had drug resistant TB. The prevalence of HIV was 14.3%. **Conclusion:** Prevalence of all forms of TB and HIV in correctional facilities has reduced by about 75% and 8.6% respectively. However, the prevalence of all forms of TB and HIV was 3.5 and 1.3 times higher than in the general population, respectively. TB/HIV programs in correctional facilities need further strengthening.

#### **ARTICLE SUMMARY**

#### Strengths and limitations of this study

- Results are generalisable as a large sample was screened.
- Variations in TB screening algorithms could have underestimated TB prevalence.
- Asymptomatic TB was not consistently screened for.

 Let a 1.

 tening algorith.

 . TB was not consistent).

# 46 INTRODUCTION

Globally, correctional facilities are disproportionately affected by tuberculosis (TB) and the Human Immunodeficiency Virus (HIV). (1-3) In some correctional facilities: the prevalence of TB has been reported to be up to 100 times higher than the prevalence in the general population (1) while the prevalence of HIV has been reported to be up to 23 times higher than the prevalence in the general population(3). Much as the living conditions in correctional facilities perpetuate TB and HIV (4, 5), incarcerated people also often come from socio-economically disadvantaged backgrounds where the burden of TB and HIV is already high. (1, 3) The prevalence of all forms of TB in Zambian correctional facilities was 6,428 per 100,000

population, in 2011, which was 18 times higher than the national estimates. (6) In the same study, 0.6% of those with bacteriologically confirmed TB had rifampicin-resistant TB and the overall prevalence of HIV was 22.9%, which was 1.5 times the national prevalence.

Since the last documented prevalence survey, several interventions including test and treat
for HIV, health systems strengthening, nutritional support, entry TB and HIV screening, among
others, have been put in place to control the burden of TB and its associated risk factors in
Zambia correctional facilities. (7-10)

2 65 4 66

This study aimed to determine current prevalence of all forms of TB, bacteriologically
confirmed TB, and drug resistant (DR) TB and the prevalence of HIV in Zambian correctional
facilities.

#### **METHODS**

#### **Study design**

We present an analysis of cross-sectional programmatic data collected by the Elton John Juvenile Offenders health (EJJOH) project during entry and mass screening of incarcerated people. The EJJOH project was a health system strengthening project aimed at supporting provision of holistic and integrated health services to juvenile offenders. While the project primarily targeted juveniles, it extended support to incarcerated adults in relation to infectious disease control. The project conducted a mass screening of inmates as part of its baseline assessment and strengthened entry screening, a routine practice in correctional revie facilities.

#### Study setting and population

Zambia has 87 correctional facilities with a total population of 21,000 incarcerated people. (11) The data was collected between July 2018 and February 2019 in 13 correctional facilities with a combined population of 9,699, representing 46.2% of the total correctional facility population in Zambia. The 13 facilities include Lusaka Central, Kamwala Remand, Livingstone Central, Katombora Reformatory School, Nakambala Approved school, Mukobeko Medium, Ndola remand, Kamfinsa State, Chingola, Insakwe Approved School, Chipata Central, Mongu Central and Kasama Central (locations shown in Supplementary Figure 1). The Reformatory and approved schools hold juveniles (persons less than 19 years old)(12); the other facilities are intended only for adults and circumstantial children(13) but also hold juveniles who are still undergoing trial.

 **BMJ** Open

91 Routinely, incarcerated people undergo TB screening and HIV testing at entry or within 7 days 92 of admission into correctional facilities. Depending on availability of logistics, periodic TB and 93 HIV mass screening are carried out, with freedom to opt out of HIV testing but not TB 94 screening and testing.

96 Study Procedures

A project specific register was used; it was a modification of the National Presumptive TB register with additional data elements on entry point, category of individual and previous history of TB. All inmates were screened for TB; those who did not opt out were tested for HIV. The screening entry point was documented under one of the following: mass screening, entry screening from the community or entry screening transfer from other correctional facility. The categories of individuals included adults, juveniles and circumstantial children. Those already on anti-TB treatment at the time of screening were documented as TB cases and those on anti-retroviral therapy (ART) were recorded as HIV positive; they were not retested. Those with cough, fever, weight loss, night sweats, chest pain and shortness of breath, irrespective of duration, were considered presumptive TB patients and submitted sputum for testing using GeneXpert (Xpert MTB/Rif Assay. Cepheid, Sunnyvale, California, USA). Symptomatic individuals with a negative GeneXpert were referred for Chest x-ray (CXR) depending on the clinician's discretion. There were 3 variations to this algorithm: 1) In Lusaka central, a random proportion of the incarcerated population received CXR in addition to symptoms screening and those with either abnormal CXR or symptoms submitted sputum for GeneXpert; 2) at Ndola remand, all except those already on TB treatment submitted sputum

2	
3	
4	
5	
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
55 54	
55	
56	
57	
58	
59	
60	

irrespective of symptoms; and 3) in Kabwe medium, Fluorescent Microscopy (FM) was usedfor sputum examination instead of GeneXpert.

115

1

Alere Determine<sup>™</sup> HIV-1/2 test (AlereHIV-1/2; Abbott, Chicago, IL, USA) was used for HIV screening and SD-Bioline HIV-1/2 (SD-Bioline HIV-1/2; Abbott, Chicago, IL, USA) for confirmation of positive screening test, following the standard Zambian HIV testing algorithm. All individuals received pre- and post-test HIV counselling. HIV positive inmates were commenced on ART within 1-2 days.

### 121 Data analysis

122 STATA Statistical Software (Stata Corporation Version 14. College Station, Texas 77845, USA) 123 was used for data analysis. A descriptive analysis was done to determine the characteristics 124 of the population screened and the prevalence of TB and HIV; overall prevalence and 125 prevalence among subgroups was determined. The prevalence of all forms of TB included 126 bacteriologically confirmed TB and clinically diagnosed TB. Bacteriologically confirmed TB 127 prevalence included those who had a positive GeneXpert or FM result, while patients already 128 on TB treatment at time of screening were excluded from this analysis since data on the type 129 of TB had not been collected. DR-TB prevalence included incarcerated people with rifampicin 130 resistance on GeneXpert. Missing data was excluded from the analysis.

Additionally, a chi-square test was done to determine if there was a statistically significant
 difference in prevalence of TB and HIV between residents and new entrants into correctional
 facilities. New entrants were defined as incarcerated people whose entry point was entry

**BMJ** Open

screening from community while residents were defined as those whose entry point was either mass screening or entry screening transfer from other correctional facility.

#### **Ethical issues**

Approval to use the programmatic data was obtained from the University of Zambia Biomedical Research Ethics Committee No: 018-11-18 and the London School of Hygiene and Tropical Medicine Ethics Committee No: 21332. The EJJOH project had obtained permission from the Zambia Correctional service and the Ministry of Community Development and Social services to conduct the screening activities. When migrating data from the paper-based registers to the electronic database, participant identifying information was excluded.

**Patient and Public involvement** 

The development of the research questions was intended to inform priority setting by the EJJOH project based on the disease burden in correctional facilities. The incarcerated population were not involved in the design of the project. The correctional health committee constituting of the incarcerated persons, correctional officers and health care workers were involved in the data collection. A representative of the correctional health committee at each correctional facility participated in the dissemination meeting on project findings.

#### RESULTS

#### Flow diagram and participant characteristics

2
3
4
5
6
7
8
9
10
11
11
12
13
14
15
16
17
18
19
20
20
∠ı วว
22
21 22 23 24 25 26
24
25
26
27
28
29 30
30
31
32
33
34
34 35
26
37 38
38
39
40
41
42
43
44
45
46
47
48
49
50
50
52
53
54
55
56
57
58
50

59 60

1 2

> 154 Of the total population of 9,699 in the 13 correctional facilities, 8164 (84.2%) were screened 155 for HIV and 8,271(85.3%) individuals were screened for TB (Figure 1). Of those screened for 156 HIV, 1170(14.3%) were HIV positive while 6994 were HIV negative. Of those screened for TB, 157 3,085 (37.3%) individuals had symptoms of TB, 5,173 (62.5%) were asymptomatic while 13 158 (0.2%) had missing data. Of the 4,278, who submitted sputum, 3,085 (72.1%) were 159 symptomatic and 1,193 (27.9%) were asymptomatic for TB. Of the asymptomatic who 160 submitted sputum 25(2.1%) were bacteriologically confirmed while of the symptomatic, 161 62(2.0%) submitted sputum. A total of 132 TB cases were identified including 87 (65.9%) 162 bacteriologically confirmed TB cases, 28 (21.2%) clinically diagnosed TB cases and 17 (12.9%) 163 that were already on TB treatment at the time of screening.

- 164 Figure 1: Flow diagram of TB screening and diagnosis
- 165

Of those screened, 7,805 (94.37%) were adults, 462 (5.59%) were juveniles while 4 (0.05%) were circumstantial children (Table 1). The overall median age (interquartile range (IQR)) of the participants was 32 years (IQR 10-93); 8,181 (98.75%) of the participants were male and 467 (5.65%) of the participants had a history of previous TB. Among those screened, 8099 (97.92%) were resident inmates while 169 (2.04%) were new entrants.

171 Table 1: Characteristics of population screened

Variable	Participants (n= 8271)
Category of individual, n (%)	
Adults	7,805 (94.37%)
Juveniles	462 (5.59%)
Circumstantial children	4 (0.05%)
Median Age (interquartile range)	
Overall	32(10-93)

Adults	33 (19-93)
Juveniles	17 (10-18)
Circumstantial children <sup>1</sup>	
Sex, n (%)	
Male	8,168 (98.75%)
Female	92 (1.11%)
Missing	11 (0.13%)
History of previous TB, n (%)	
Yes	467 (5.65%)
No	7,790 (94.18%)
Missing	14 (0.17%)
Type of screening visit, n (%)	
Mass screening	7,602 (91.92%)
Entry screening other correctional facility	497 (6.01%)
Entry screening community	169 (2.04%)
Missing	3 (0.03%)

#### 

# 174 Prevalence of all forms of TB and bacteriologically confirmed TB

The overall prevalence of all forms of TB was 1,598 (1339-1892) per 100,000 population while the overall prevalence of bacteriologically confirmed TB was 1,056 (844-1301) per 100,000 population (Table 2). There was no statistically significant difference in the prevalence of both all forms of TB and bacteriologically confirmed TB between males and females (p=0.51) and (p=1.00) respectively. It was the same for adults and juveniles (p= 0.82) and (p= 0.23) for the respective types of TB. There were no prevalent TB cases among circumstantial children.

# 181 Table 2: Prevalence of all forms of TB and bacteriologically confirmed TB

Cases/ Participants (n/N)	Prevalence of all forms of TB per 100,000 (CI)	p- value	(n/N)	Prevalence of Bacteriologically confirmed TB per 100,000 (CI)	p- value
---------------------------------	---	-------------	-------	--	-------------

	Overall	132/8,2582	1598 (1339-1892)		87/8,241 <sup>2,3</sup>	1056 (844-1301)	
			(1333-1892)	Sex			
	Male	129/8,155	1582 (1322-1877)	0.51	84/8,138	1032 (824-1276)	1.00
	Female	1/92	1087 (27- 5908)	0.51	1/92	1087 (27- 5908)	_ 1.00
	Missing gender	2/11			2/11		
			Category	of indiv	ridual		-
	Adult inmate	124/7,792	1591 (1325- 1894)	0.82	79/7,775	1016 (805-1265)	0.22
	Juvenile inmate	8/462	1732 (750-3383)	0.82	8/462	1732 (750-3383)	- 0.23
	Circumstantial children	0/4	0 (0-60236) *		0/4	0 (0-60236) *	
182 183 184 185 186 187	<ul> <li><sup>2</sup> Thirteen (13) participants had missing values on TB.</li> <li><sup>3</sup> Seventeen participants were already on TB treatment, bacteriological status unknown (*) one-sided, 97.5% confidence interval</li> <li>The differences in prevalence of all forms TB and bacteriologically confirmed TB between residents and new entrants in correctional facilities were not statistically significant (<i>p</i>= 0.25)</li> </ul>						
188 189	and ( <i>p</i> =0.21) resp				0,7/	,	
190	Prevalence of DR TB						
191	Among the bacteriologically confirmed TB cases, the overall prevalence of DR-TB was 4.6%						
192	(1.3%-11.4%) (Table 3). There was no statistically significant difference in prevalence of DR-						
193	TB between males and females (p=0.95), between adults and juveniles (p=0.68) and between						
194	those with and those without previous history of TB (p=0.72).						
195							
196	Table 3: Prevalence of drug resistant TB						

1
2
3
4 5
5 6
7
8
9
10 11
12
13
14
15 16
17
18
19 20
20 21
22
23
24
25 26
27
28
29
30 31
32
33
34
35 36
37
38
39
40 41
42
43
44
45 46
40 47
48
49
50 51
51 52
53
54
55 56
56 57
58
59
60

197

198 199

	Cases/ Participants (n/N)	Prevalence of DR TB % (CI)	p-value		
Overall	4/87	4.6 (1.3-11.4)			
	Se	ex execution of the second sec	1		
Male	4/84	4.8 (1.3-11.7)	0.95		
Female	0/1	0 (0- 97.5) *			
Missing	0/2				
Category of individual					
Adult incarcerated people	4/79	5.1 (1.4- 12.5)	0.68		
Juveniles	0/8	0 (0-3.7) *			
Circumstantial children	0/0	0			
	Previous Hi	story of TB			
No	3/64	4.7 (1.0-13.1)	0.72		
Yes	1/23	4.3 (0.1-21.9)			

\* one-sided, 97.5% confidence interval

There was no statistically significant difference in prevalence of DR TB between resident

200 incarcerated people and new entrants into correctional facilities (p= 0.26).

### 201 **Prevalence of HIV**

The overall HIV prevalence was 14.3% (13.6%-15.1%) (Table 4). The prevalence of HIV among males was 14.1% (13.4%-14.9%) and among females 25.0% (16.6%-35.1%) (p=0.01). The prevalence of HIV among adults and juveniles was 15.0% (14.1%-15.7%) and 3.9% (2.3%-6.2%) (p<0.01). There were no prevalent HIV cases among circumstantial children.

206 Table 4: Prevalence of HIV

	Cases/ Participants (n/N)	Prevalence of HIV % (CI)	p-value
Overall	1,170/8,1644	14.3	
		(13.6-15.1)	
	Sex		

2	
3	
4	
5	
6	
7	
8	
9	
10	
11	
12	
13	
12 13 14 15 16 17	
15	
16	
17	
18	
19	
20	
21 22	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
20	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
55 54	
55	
56	
50 57	
58	
58 59	
59 60	
00	

208

209

210

213 214

1

Male	1,139/8,062	14.1	0.01	
		(13.4-14.9)		
Female	23/92	25.0		
		(16.6-35.1)		
Missing sex	8/10			
Category of individual				
Adults	1,153/7,727	15.0	0.00	
		(14.1-15.7)		
Juveniles	17/433	3.9 (2.3- 6.2)		
<u>a</u> :				
Circumstantial	0/4	0 (0-60.2) *		

<sup>4</sup> One hundred and seven (107) participants either opted out of HIV testing or had missing data (\*) one-sided, 97.5% confidence interval. \*\* not determined.

211 The differences in prevalence of HIV between residents and new entrants into correctional

212 facilities were not statistically significant (*p*=0.05) (Supplemental Table 1).

# 215 **DISCUSSION**

This study found that in Zambian correctional facilities, the prevalence of all forms of TB, bacteriologically confirmed TB and DR-TB were 3.5 times higher, 1.7 times higher and almost twice as high as in the general population, respectively. (14, 15) Additionally, the prevalence of HIV was 1.3 times higher than the prevalence in the general population (16). 25.8% of the bacteriologically confirmed TB cases were asymptomatic.

In comparison to the 2010-2011 study, the prevalence of all forms of TB had reduced by about
75%, the prevalence of bacteriologically confirmed TB has reduced by 50% but the prevalence
of DR-TB has increased by 4%. (6) The prevalence of DR-TB among people with no history of
TB is similar to the prevalence among people with previous history of TB, suggesting

#### **BMJ** Open

significant transmission of DR-TB either in correctional facilities or in the communities where the incarcerated people come from, or both. Strengthening TB infection control can reduce transmission of DR-TB. (17) There has been an 8.6% reduction in prevalence of HIV since the study in 2010-2011. (6) Similar to the national picture, the prevalence of HIV was higher among adults than juvenile incarcerated people and was higher among females than males. (16) However, the prevalence of HIV in women relative to the prevalence of HIV in men is much higher in the incarcerated population than the general population because women with HIV risk factors like sex worker status, intimate partner violence, drug and substance abuse are overrepresented in this population. (18)

The difference in prevalence of TB and HIV between residents and new entrants into correctional facilities was not statistically significant. This is possibly due to the following reasons: a) individuals entering correctional facilities come from socio-economically disadvantaged backgrounds where prevalence of TB and HIV are already high (1); b) there are high rates of recidivism (19); and c) detainees spend long periods in police cells, which have similar conditions to the correctional facilities (20, 21).

The results of our study are generalizable to all correctional facilities in Zambia, as a large sample of the inmate population, representing 36.3% of the total correctional facility population, was screened.(11) However, there were variations in the strength of screening algorithms for TB, hence the prevalence of TB could have been underestimated in some correctional facilities. Additionally, asymptomatic TB was not consistently screened for.

1,

#### CONCLUSION 248

3 4 5 6	248	CONCLUSION
7 8 9	249	Despite significant progress over the last decade in controlling TB and HIV in Zambian
10 11	250	correctional facilities, these continue to be disproportionately affected by both diseases.
12 13 14	251	TB/HIV programs in correctional facilities need further strengthening including aspects of
15 16	252	gender responsive HIV programming. Additional studies that screen for asymptomatic TB are
17 18 19	253	required.
20 21	254	
22 23 24	255	REFERENCES
24	256	1. World Health Organization. Tuberculosis in Prisons [cited 2020 20th July 2020]. Available
26	257	from: https://www.who.int/tb/areas-of-work/population-groups/prisons-facts/en/.
27	258	2. Telisinghe L, Charalambous S, Topp SM, Herce ME, Hoffmann CJ, Barron P, et al. HIV and
28	259	tuberculosis in prisons in sub-Saharan Africa. The Lancet. 2016;388(10050):1215-27.
29	260	3. Dolan K, Wirtz AL, Moazen B, Ndeffo-Mbah M, Galvani A, Kinner SA, et al. Global burden of
30	261	HIV, viral hepatitis, and tuberculosis in prisoners and detainees. The Lancet. 2016;388(10049):1089-
31	262	102.
32	263	4. Reid SE, Topp SM, Turnbull ER, Hatwiinda S, Harris JB, Maggard KR, et al. Tuberculosis and
33 34	264	HIV control in sub-Saharan African prisons: "thinking outside the prison cell". Journal of Infectious
35	265	Diseases. 2012;205(suppl 2):S265-S73.
36	266	5. World Health Organization Regional Office for Europe. Prisons and health. Copenhagen,
37	267	Denmark2014. 45-70, 83 p.
38	268	6. Maggard KR, Hatwiinda S, Harris JB, Phiri W, Krüüner A, Kaunda K, et al. Screening for
39	269	tuberculosis and testing for human immunodeficiency virus in Zambian prisons. Bulletin of the World
40	270	Health Organization. 2015;93:93-101.
41	271	7. Ubumi Prisons Iniative. Zambian Prisons [updated 4th August 2020; cited 2020 4th August
42	272	2020]. Available from: <u>https://ubumi.net/zambian_prisons.html</u> .
43 44	273	8. Herce ME, Hoffmann CJ, Fielding K, Topp SM, Hausler H, Chimoyi L, et al. Universal test-and-
45	274	treat in Zambian and South African correctional facilities: a multisite prospective cohort study. The
46	275	Lancet HIV. 2020;7(12):e807-e16.
47	276	9. Topp SM, Sharma A, Moonga CN, Chileshe C, Magwende G, Henostroza G. Evaluation of a
48	277	health system strengthening initiative in the Zambian prison system. BMJ global health. 2018;3(1).
49	278	10. Herce ME, Muyoyeta M, Topp SM, Henostroza G, Reid SE. Coordinating the prevention,
50	279	treatment, and care continuum for HIV-associated tuberculosis in prisons: a health systems
51	280	strengthening approach. Current Opinion in HIV and AIDS. 2018;13(6):492.
52 53	281	11. Institute of Crime and Justice Policy Research B. World Prison Brief 2020 [cited 2020 21st
55 54	282	July 2020]. Available from: https://www.prisonstudies.org/country/zambia.
55	283	12. Government of the Republic of Zambia. The Juvenile Act. Chapter 53 of the Laws of
56	284	Zambia1964.
57	285	13. Government of the Republic of Zambia. The Prisons Act Zambia: Government Printer; 2004
58	286	[cited 2020 13th May 2020]. Available from:
59	287	http://www.parliament.gov.zm/sites/default/files/documents/acts/Prisons%20Act.pdf.
60	_0,	

1 2		
2	288	14. Kapata N, Mbulo G, Cobelens F, de Haas P, Schaap A, Mwamba P, et al. The second Zambian
4	289	national tuberculosis drug resistance survey–a comparison of conventional and molecular methods.
5 6	290	Tropical Medicine & International Health. 2015;20(11):1492-500.
7	291	15. Kapata N, Chanda-Kapata P, Ngosa W, Metitiri M, Klinkenberg E, Kalisvaart N, et al. The
8	292	prevalence of tuberculosis in Zambia: results from the first national TB prevalence survey, 2013–
9 10	293 294	2014. PLoS One. 2016;11(1):e0146392. 16. Ministry of Health Zambia. Zambia Population-based HIV Impact assessment 2016. Lusaka;
10	294	16. Ministry of Health Zambia. Zambia Population-based HIV Impact assessment 2016. Lusaka; 2019.
12	296	17. Organization WH. WHO policy on TB infection control in health-care facilities, congregate
13	297	settings and households. World Health Organization; 2009. Report No.: 9241598328.
14 15	298	18. United Nations Office on Drug and Crime U. Women and HIV in prison settings Austria2008
16	299	[cited 2021 1st February 2021]. Available from:
17	300	https://www.unodc.org/documents/middleeastandnorthafrica/drug-prevention-health-
18 19	301 302	<ul> <li>publications/WOMEN_AND_HIV_IN_PRISON_SETTINGS.pdf.</li> <li>19. Yukhnenko D, Sridhar S, Fazel S. A systematic review of criminal recidivism rates worldwide:</li> </ul>
20	302	3-year update. Wellcome open research. 2019;4.
21	304	20. Todrys KW. Unjust and Unhealthy: Hiv, Tb, and Abuse in Zambian Prisons. 2010.
22	305	21. Henostroza G, Topp SM, Hatwiinda S, Maggard KR, Phiri W, Harris JB, et al. The high burden
23 24	306	of tuberculosis (TB) and human immunodeficiency virus (HIV) in a large Zambian prison: a public
25	307	health alert. PloS one. 2013;8(8):e67338.
26	308	
27 28		
28 29	200	ACKNOWLEDGEMENT
30	309	
31 22		
32 33	210	The Zearbin Convertional Control Multiple of Control Day allowed and the stability of Control Day and
34	310	The Zambia Correctional Service, Ministry of Community Development and Social Welfare and
35	311	the correctional health committees are acknowledged for the support provided to the EJJOH
36 37	511	the correctional health committees are acknowledged for the support provided to the Enorm
38	312	project team during data collection. Innocent Mwaba is acknowledged for drawing the map
39	512	
40 41	313	showing study sites.
42		
43	314	
44 45		
45 46		
47	315	FUNDING
48	515	
49 50		
51	316	This research was funded by the Elton John AIDS Foundation; no grant number received.
52	510	This rescurent was funded by the Enton sonn Abor Foundation, no grant hander received.
53	317	
54 55		
56		
57		
58 59		
60		

### 

# 318 AUTHOR CONTRIBUTIONS

- 319 Conceived and designed the study: MK, SH, CNM, MM. Database design and data curation:
- 320 PS, JB. Implemented the study: MK, SH, MT, TZ, CNM, MM. Data analysis: PS, MK, FB. Wrote
- 321 the original draft: MK. Reviewed the manuscript: SH, MT, JB, PS, TZ, FB, CNM, MM. Approved
- 322 the final version to be published: MK, SH, PS, MT, JB, TZ, FB, CNM, MM.
- 323 The corresponding author attests that all listed authors meet authorship criteria and that no
- 324 others meeting the criteria have been omitted.


326 CONFLICT OF INTEREST


327 The authors declare no conflict of interest.

# 329 DATA SHARING STATEMENT

330 Additional data is available upon request by emailing Monde.Muyoyeta@cidrz.org

Page 19 of 22





1	
2	
3	
4	
5	
6	
7	
8	
8 9 10 11	
10	
11	
12 13	
13	
14	
15 16 17	
16	
17	
18	
19	
20 21 22 23	
21	
22	
23	
24 25	
25	
26	
26 27	
28	
29	
30	
31	
32	
33	
34 35	
36	
20	
36 37 38	
39 40	
40	
41	
42	
43	
44 45	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
50	

59 60 Supplementary Table 1: Difference in prevalence of TB and HIV between resident incarcerated people and new entrants

Type of TB	Cases/ Participants (n/N)	Residents	Cases/ Participants (n/N)	New Entrants	P- value
All forms TB prevalence per 100,000 per 100,000 population (CI)	121/7,780	1555 (1280-1830)	11/496	2218 (917- 3518)	0.25
Bacteriologically confirmed TB prevalence per 100,000 population (CI)	79/7,763	1018 (794- 1241)	8/496	1613 (500- 2725)	0.21
DR TB prevalence	3/76	3.9 (0.8-10.7)	1/8	12.5 (0.4-52.7)	0.26
HIV prevalence % (CI)	1,119/7,722	14.5 (13.7-15.3)	52/462	11.3 (8.4-14.1)	0.05

1
2
3
4
5 6
-
/ 8
8 9
9 10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32 33
33 34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54 57
55 56
56 57
57 58
58 59
59 60

STROBE Statement—Checklist of items that should be included in reports of <i>cross-sectional studies</i>	

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or	2
		the abstract	
		(b) Provide in the abstract an informative and balanced summary of what	2
		was done and what was found	
Introduction			_
Background/rationale	2	Explain the scientific background and rationale for the investigation being	3
		reported	
Objectives	3	State specific objectives, including any prespecified hypotheses	3
Methods			
Study design	4	Present key elements of study design early in the paper	4
Setting	5	Describe the setting, locations, and relevant dates, including periods of	4,5
8		recruitment, exposure, follow-up, and data collection	,-
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection	5,6
1		of participants	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders,	6
		and effect modifiers. Give diagnostic criteria, if applicable	
Data sources/	8*	For each variable of interest, give sources of data and details of methods	5,6
measurement	-	of assessment (measurement). Describe comparability of assessment	
		methods if there is more than one group	
Bias	9	Describe any efforts to address potential sources of bias	5
Study size	10	Explain how the study size was arrived at	5
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If	6
		applicable, describe which groupings were chosen and why	
Statistical methods	12	( <i>a</i> ) Describe all statistical methods, including those used to control for	6
		confounding	
		(b) Describe any methods used to examine subgroups and interactions	6
		(c) Explain how missing data were addressed	6
		(d) If applicable, describe analytical methods taking account of sampling	
		strategy	
		(e) Describe any sensitivity analyses	
		(c) Describe any sensitivity analyses	1
Results	13*	(a) Depart numbers of individuals at each store of study or numbers	8
Participants	13.	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included	0
		in the study, completing follow-up, and analysed	
		(b) Give reasons for non-participation at each stage	8
			8
Descriptions data	1.4*	(c) Consider use of a flow diagram	1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical,	8,9
		social) and information on exposures and potential confounders	0.12
		(b) Indicate number of participants with missing data for each variable of interest	9-12
Outcome data	15*	interest	0.12
Outcome data	15*	Report numbers of outcome events or summary measures	9-12
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted	
		estimates and their precision (eg, 95% confidence interval). Make clear	
		which confounders were adjusted for and why they were included	
			L

	(b) Report category boundaries when continuous variables were	9-1
	categorized	
	(c) If relevant, consider translating estimates of relative risk into absolute	
	risk for a meaningful time period	
17	Report other analyses done-eg analyses of subgroups and interactions,	9-1
	and sensitivity analyses	
18	Summarise key results with reference to study objectives	12
19	Discuss limitations of the study, taking into account sources of potential	13
	bias or imprecision. Discuss both direction and magnitude of any potential	
	bias	
20	Give a cautious overall interpretation of results considering objectives,	12
	limitations, multiplicity of analyses, results from similar studies, and other	13
	relevant evidence	
21	Discuss the generalisability (external validity) of the study results	13
22	Give the source of funding and the role of the funders for the present study	15
	and, if applicable, for the original study on which the present article is	
	based 🚫	
	18       19       20       21	categorized         (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period         17       Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses         18       Summarise key results with reference to study objectives         19       Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias         20       Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence         21       Discuss the generalisability (external validity) of the study results         22       Give the source of funding and the role of the funders for the present study

\*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.

# **BMJ Open**

### A cross sectional assessment of Tuberculosis and Human Immunodeficiency Virus prevalence in 13 correctional facilities in Zambia

Journal:	BMJ Open
Manuscript ID	bmjopen-2021-052221.R1
Article Type:	Original research
Date Submitted by the Author:	23-Jun-2021
Complete List of Authors:	Kagujje, Mary; Center for Infectious Disease Research in Zambia, Tuberculosis department Somwe, Paul; Center for Infectious Disease Research in Zambia, Strategic Information department Hatwiinda, Sisa; Center for Infectious Disease Research in Zambia, Tuberculosis department Bwalya, Joel; Center for Infectious Disease Research in Zambia, Strategic Information department Zgambo, Tamala; Zambia Correctional Service Thornicroft, Moomba; Center for Infectious Disease Research in Zambia, Tuberculosis department Bozzani, Fiammetta; London School of Hygiene and Tropical Medicine Faculty of Public Health and Policy Moonga, Clement; Center for Infectious Disease Research in Zambia Muyoyeta, Monde ; Center for Infectious Disease Research in Zambia
<b>Primary Subject Heading</b> :	Epidemiology
Secondary Subject Heading:	Infectious diseases
Keywords:	Tuberculosis < INFECTIOUS DISEASES, HIV & AIDS < INFECTIOUS DISEASES, EPIDEMIOLOGY, PUBLIC HEALTH

# SCHOLARONE<sup>™</sup> Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

review only

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

3	
4	
5	
6	
7	
8	
9	
) 10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
22	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	

1	A cross sectional assessment of Tuberculosis and Human
2	Immunodeficiency Virus prevalence in 13 correctional
3	facilities in Zambia
4	

5 Mary Kagujje (0000-0003-4818-6548)<sup>1</sup>, Paul Somwe<sup>2</sup>, Sisa Hatwiinda<sup>1</sup>, Joel Bwalya<sup>2</sup>, Tamala 6 Zgambo<sup>3</sup>, Moomba Thornicroft<sup>1</sup>, Fiammetta Bozzani<sup>4</sup>, Clement Nchimunya Moonga<sup>1</sup>, Monde 7 Muyoyeta<sup>1</sup> 8 **Author affiliations** 9 1. Tuberculosis department, Centre for Infectious Disease Research in Zambia, P.O. Box 34681 10 Lusaka, Zambia 10101 11 2. Strategic Information department, Centre for Infectious Disease Research in Zambia, P.O. Box 12 34681 Lusaka, Zambia 10101 13 3. Zambia Correctional Service, P.O. Box 80926 Kabwe, Zambia 10101 14 4. London School of Hygiene and Tropical Medicine, Keppel Street London WCIE 7HT, United 15 Kingdom 16 Correspondence to Mary Kagujje; <a href="mailto:mkagujje@gmail.com">mkagujje@gmail.com</a> 17 18 19 Key words: Correctional facilities, Tuberculosis, HIV, Zambia 20 21

# 22 ABSTRACT

**Objective:** To determine the prevalence of Tuberculosis (TB) and Human Immunodeficiency

- 24 virus (HIV) in 13 Zambian correctional facilities.
- 25 Methods: Cross sectional study
- Setting: 13 correctional facilities in 7 of the 10 provinces in Zambia.

**Participants:** All incarcerated individuals were eligible for TB and HIV screening and testing.

28 Of the total study population of 9,695 individuals, which represent 46.2% of total correctional

23 29 population at the beginning of the study, 8,267 and 8,160 were screened for TB and HIV

30 respectively.

31 Interventions: TB and HIV screening and testing was done between July 2018 and February
 32 2019.

33 Primary outcome measures: All forms of TB, bacteriologically confirmed TB, drug resistant
 34 TB, HIV

**Results:** Prevalence of all forms of TB and bacteriologically confirmed TB was 1598 per 100,000 population and 1056 per 100,000 population, respectively. Among those with bacteriologically confirmed TB, 4.6% had drug resistant TB. The prevalence of HIV was 14.3%. **Conclusion:** Compared to the study in 2011 which screened inmates representing 30% of the country's inmate population then, the prevalence of all forms of TB and HIV in correctional facilities has reduced by about 75% and 8.6% respectively. However, compared to the general population, the prevalence of all forms of TB and HIV was 3.5 and 1.3 times higher, respectively. TB/HIV programs in correctional facilities need further strengthening.

#### **ARTICLE SUMMARY** Strengths and limitations of this study This is the only study on prevalence of TB and HIV in Zambian correctional facilities in the past 8 years. Results are generalisable to the 13 correctional facilities as a large sample was screened for TB and HIV. Data disaggregates can inform targeted interventions to reduce the burden of both diseases. Variations in TB screening algorithms could have underestimated TB prevalence. Asymptomatic TB was not consistently screened for. reliez onz

# 54 INTRODUCTION

Globally, correctional facilities are disproportionately affected by tuberculosis (TB) and the Human Immunodeficiency Virus (HIV). (1-3) In some correctional facilities: the prevalence of TB has been reported to be up to 100 times higher than the prevalence in the general population (1) while the prevalence of HIV has been reported to be up to 23 times higher than the prevalence in the general population(3). The poor living conditions in correctional facilities perpetuate TB and HIV. While overcrowding, poor ventilation, HIV, poor nutrition and late case detection perpetuate TB; sexual violence, sharing of sharp objects and lack of access to condoms perpetuate HIV. (4, 5) Additionally, incarcerated people often come from socio-economically disadvantaged backgrounds where the burden of TB and HIV is already high. (1, 3)

In 2011, the prevalence of all forms of TB in 6 Zambian correctional facilities representing 30%
of the total incarcerated population was 6,428 per 100,000 population, which was 18 times
higher than the national estimates. (6) In the same study, 0.6% of those with bacteriologically
confirmed TB had rifampicin-resistant TB and the overall prevalence of HIV was 22.9%, which
was 1.5 times the national prevalence.

Since the last documented prevalence survey, several interventions including test and treat
for HIV, health systems strengthening, nutritional support, TB and HIV entry screening, among
others, have been put in place to control the burden of TB and its associated risk factors in
Zambia correctional facilities. (7-10)

This study aimed to determine current prevalence of all forms of TB, bacteriologically
confirmed TB, and drug resistant (DR) TB and the prevalence of HIV in 13 Zambian correctional
facilities.

# 80 METHODS

### 81 Study design

We present an analysis of cross-sectional data collected under programmatic conditions by the Elton John Juvenile Offenders' health (EJJOH) project. The EJJOH project was a health system strengthening project aimed at supporting provision of holistic and integrated health services to juvenile offenders. While the project primarily targeted juveniles, where these were held in adults' facilities, support was extended to incarcerated adults in relation to infectious disease control. The project screened as part of its baseline assessment.

# 88 Study setting and population

Zambia has 87 correctional facilities with a total capacity of 9,150 incarcerated individuals. (11) However, the total incarcerated population in Zambia was slightly over 21,000 in 2018 and 22,823 in 2019. In 2019, almost one in five individuals detained was in pre-trial detention. (11) The data was collected between July 2018 and February 2019 in 13 correctional facilities with a combined population of 9,695, representing 46.2% of the total correctional facility population in Zambia in 2018. The 13 correctional facilities had been purposefully selected by the EJJOH project because they held a significant number of juveniles. The facilities include; Lusaka Central, Kamwala Remand, Livingstone Central, Katombora Reformatory School,

#### **BMJ** Open

3			
4			
5			
6			
7			
8			
9			
	0		
	1		
1			
	3		
	4		
	5		
1	6		
1	7		
	8		
	9		
י כ	0		
2 7	1		
2	1		
2	2		
2	3		
2	4		
2	5		
2	6		
2	7		
2	8		
2 ว	ი ი		
2	9 0		
3	0		
3	1 2 3		
3	2		
3	3		
3	4		
3	5		
3	6		
3	7		
כ ר	/ 8		
3	8 9		
3	9		
	0		
4	1		
4	2		
4	3		
	4		
	5		
	5 6		
4			
	8		
	9		
5	0		
	1		
5			
5			
	3 4		
	5		
	6		
5			
5	8		
5	9		

103

97 Nakambala Approved school, Mukobeko Medium, Ndola remand, Kamfinsa State, Chingola, 98 Insakwe Approved School, Chipata Central, Mongu Central and Kasama Central (locations 99 shown in Supplementary Figure 1). The Reformatory and approved schools hold ordered 100 (convicted) juveniles (persons less than 19 years old)(12); the other facilities are intended only 101 for adults and circumstantial children(13) but also hold juveniles who are still undergoing 102 trial.

- Across Zambia, routinely, incarcerated people should undergo universal TB screening and HIV testing at entry or within 7 days of admission into correctional facilities. However, in some facilities entry screening is not done due to various constraints. Depending on availability of logistics, periodic TB and HIV mass screening are carried out, with freedom to opt out of HIV testing but not TB screening and testing. TB screening is mandatory to increase early TB detection and treatment so as to protect other inmates from TB.
- 110

### 111 Study Procedures

112 A project specific register was used; it was a modification of the National Presumptive TB 113 register with additional data elements on entry point, category of individual and previous 114 history of TB. All inmates were screened for TB; those who did not opt out were tested for 115 HIV. The screening point was documented under one of the following categories: mass 116 screening, entry screening from the community or entry screening transfer from other 117 correctional facility. The categories of individuals included adults and juveniles. Those already 118 on anti-TB treatment at the time of screening were documented as TB cases and those on 119 anti-retroviral therapy (ART) were recorded as HIV positive and were not retested. Those with 60

cough, fever, weight loss, night sweats, chest pain and shortness of breath, irrespective of duration, were considered presumptive TB patients and submitted sputum for testing using GeneXpert (Xpert MTB/Rif Assay. Cepheid, Sunnyvale, California, USA). Symptomatic individuals with a negative GeneXpert were referred for Chest x-ray (CXR) depending on the clinician's discretion. There were 3 variations to this algorithm: 1) In Lusaka central, a random proportion of the incarcerated population received CXR in addition to symptoms screening and those with either abnormal CXR or symptoms submitted sputum for GeneXpert; 2) at Ndola remand, all except those already on TB treatment submitted sputum irrespective of symptoms; and 3) in Kabwe medium, Fluorescent Microscopy (FM) was used for sputum examination instead of GeneXpert.

Alere Determine<sup>™</sup> HIV-1/2 test (AlereHIV-1/2; Abbott, Chicago, IL, USA) was used for HIV screening and SD-Bioline HIV-1/2 (SD-Bioline HIV-1/2; Abbott, Chicago, IL, USA) for confirmation of positive screening test, following the standard Zambian HIV testing algorithm. All individuals received pre- and post-test HIV counselling. HIV positive inmates were commenced on ART within 1-2 days.

### **Data analysis**

STATA Statistical Software (Stata Corporation Version 14. College Station, Texas 77845, USA)
 was used for data analysis. A descriptive analysis was done to determine the characteristics
 of the population screened and the prevalence of TB and HIV; overall prevalence and
 prevalence among subgroups was determined. The prevalence of all forms of TB included
 bacteriologically confirmed TB and clinically diagnosed TB. Bacteriologically confirmed TB
 prevalence included those who had a positive GeneXpert or FM result, while patients already

**BMJ** Open

on TB treatment at time of screening were excluded from this analysis since data on the type of TB had not been collected. DR TB prevalence included incarcerated people with rifampicin resistance on GeneXpert. Missing data was excluded from the analysis. Additionally, a chi-square test was done to determine if there was a statistically significant difference in prevalence of TB and HIV between residents and new entrants into correctional facilities. New entrants were defined as incarcerated people whose entry point was entry screening from community while residents were defined as those whose entry point was either mass screening or entry screening transfer from other correctional facility. **Patient and Public involvement** The development of the research questions was intended to inform priority setting by the EJJOH project based on the disease burden in correctional facilities. The incarcerated population were not involved in the design of the project. The correctional health committee constituting of the incarcerated persons, correctional officers and health care workers were involved in the data collection. A representative of the correctional health committee at each correctional facility participated in the dissemination meeting on project findings. RESULTS 

160 Flow diagram and participant characteristics

161 Of the total adult and juvenile population of 9,695 in the 13 correctional facilities, 8160
162 (84.2%) were screened for HIV and 8,267(85.3%) were screened for TB (Figure 1). Individuals

not screened were 1,428 (14.7%) and they constituted those either in court or the farms. Of those screened for HIV, 1170(14.3%) were HIV positive, of which 816 were known positive and 354 were new positives, while 6,990 (85.7%) were HIV negative. Of those screened for TB, 17(0.2%) were already on treatment, 3,076 (37.3%) individuals had symptoms of TB, 5,161 (62.5%) were asymptomatic while 13 (0.2%) had missing data. A total of 4,269 individuals had documented sputum results. Eighty seven (87) bacteriologically confirmed TB cases were reported including 25(28.7%) asymptomatic individuals 62(71.3%) symptomatic individuals. A total of 132 TB cases were identified including 87 (65.9%) bacteriologically confirmed TB cases, 28 (21.2%) clinically diagnosed TB cases and the 17 (12.9%) that were already on TB treatment at the time of screening. Figure 1: Flow diagram of TB screening and diagnosis

Of those screened, 7,805 (94.41%) were adults and 462 (5.58%) were juveniles (Table 1). The overall median age (interquartile range (IQR)) of the participants was 32 years (IQR 10-93); the median ages for the adults and juveniles were 33(IQR 19-93) and 17(IQR 10-18) respectively. The males were 8,167 (98.79%), participants with a history of previous TB were 467 (5.65%), resident inmates were 7,767 (93.95%) while new entrants were 497 (6.01%).

180 Table 1: Characteristics of population screened

Variable	Participants (n= 8267)
Category of individual	n (%)
Adults	7,805 (94.41%)
Juveniles	462 (5.58%)
Median Age (IQR)	
Overall	32(10-93)
Adults (≥19 years)	33 (19-93)

1	
1	
2	
3	
4	
5	
2	
6	
7	
8	
9	
-	0
1	1
1	2
1	3
1	Δ
	- -
1	
1	6
1	7
1	8
1	9
1	9
2	
2	1
2	2
2	
2	2
2	4
2	5
2	6
2	7
2	, 8
2	9
3	0
3	1
3	
2	2
3	3
3	4
3	5
3	6
	7
3	1
	8
	9
4	0
4	
4	
4	
4	4
4	5
4	
4	
4	8
4	9
	0
5	
5	
5	
5	3
5	
	-

Juveniles (<19 years)	17 (10-18)		
Sex	n (%)		
Male	8,167 (98.79%)		
Female	89 (1.08%)		
Missing	11 (0.13%)		
History of previous TB	n (%)		
Yes	467 (5.65%)		
No	7,786 (94.18%)		
Missing	14 (0.17%)		
Type of screening visit	n (%)		
Mass screening	7,602 (91.92%)		
Entry screening other correctional facility	165 (2.00%)		
Entry screening community	497 (6.01%)		
Missing	3 (0.04%)		

181 Abbreviations: IQR- Interquartile range, TB- Tuberculosis

182

# 183 Prevalence of all forms of TB and bacteriologically confirmed TB

The overall prevalence of all forms of TB was 1,598 (1339-1892) per 100,000 population while the overall prevalence of bacteriologically confirmed TB was 1,056 (844-1301) per 100,000 population (Table 2). There was no statistically significant difference in the prevalence of both all forms of TB and bacteriologically confirmed TB between males and females, (p=0.51) and (p=1.00) respectively. It was the same for adults and juveniles (p= 0.82) and (p= 0.23) respectively and the new entrants and residents (p=0.25) and (p=0.21) respectively.

190	Table 2: Prevalence of all forms of TB and bacteriologically confirmed TB
-----	---

	Cases/ Participants (n/N)	Prevalence of all forms of TB per 100,000 (CI)	p- value	Cases/ Participants (n/N)	Prevalence of Bacteriologically confirmed TB per 100,000 (CI)	p- value
Overall	132/8,2541	1599 (1340-1894)		87/8,237 <sup>1,2</sup>	1056 (847-1301)	

				Sex			
	Male	129/8,154	1582 (1322-1877)		84/8,137	1032 (824-1276)	
	Female	1/89	1124 (28- 6102)	0.60	1/89	1124 (28- 6102)	- 0.79
	Missing gender	2/11			2/11		
			Category	of indiv	ridual		
	Adult (≥19 years)	124/7,792	1591 (1325- 1894)		79/7,775	1016 (805-1265)	
	Juvenile (<19 years)	8/462	1732 (750-3383)	0.82	8/462	1732 (750-3383)	- 0.23
				y point <sup>1,7</sup>	3		
	Residents	121/7757	1560 (1296- 1861)	0.25	79/7740	1020 (809-1270)	0.21
	New entrants	11/494	2227 (1117-3949)		8/494	1619 (702-3166)	_
2 3 4 5 6 7 8	Residents include the other correctional fa New entrants include <sup>1</sup> Thirteen (13) partic <sup>2</sup> Seventeen participan <sup>3</sup> Three (3) participan <b>Prevalence of</b>	cility. e those screened ur ipants had missing ints were already o ts had missing value	nder entry screening values on TB. n TB treatment, bac	g from the	community (polic		
						· · · · · · · · · · · · · · · · ·	
)	Among the bacte	eriologically cont	irmed TB cases,	the ove	rall prevalence	of DR TB was 4.6%	
)	(1.3%-11.4%) (Tal	ole 3). There was	s no statistically	significar	nt difference in	prevalence of DR TB	
	between males a	nd females (p=0	.95), between a	dults and	l juveniles (p=0	.68), between those	
	with and those without previous history of TB (p=0.72) and between the new entrants and						
	with and those w	ithout previous	nistory of TB (p	-0.72j u		e new entrants and	
2	with and those w residents(p=0.26)		nistory of TB (p	,-0.72) u		e new entrants and	

י ר	
2	
3	
4	
5	
6	
7	
7 8	
ð	
9	
10	
11	
12	
13	
14	
14	
15	
16	
17	
17 18	
19	
20	
21	
22	
23	
24	
25	
26	
20	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
3/	
38	
39	
40	
41	
42	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	

	Cases/ Participants (n/N)	Prevalence of DR TB % (CI)	p-value
Overall	4/87	4.6 (1.3-11.4)	
	S	ex	
Male	4/84	4.8 (1.3-11.7)	0.95
Female	0/1	0 (0- 97.5) *	
Missing	0/2		
	Category o	of individual	
Adults (≥19 years)	4/79	5.1 (1.4- 12.5)	0.68
Juveniles (<19 years)	0/8	0 (0-3.7) *	-
	Previous H	istory of TB	
No	3/64	4.7 (1.0-13.1)	0.72
Yes	1/23	4.3 (0.1-21.9)	-
	Entry	/ point	
Residents	3/76	3.8 (0.8-10.7)	0.26
New entrants	1/8	12.5 (0.3-52.7)	-
Residents include those screened other correctional facility. New incarcerated individuals inclu	de those screened u		
	erval		
Prevalence of HIV			
<b>Prevalence of HIV</b> The overall HIV prevalence v	vas 14.3% (13.6%	-15.1%) (Table 4). The prev	valence of HIV amo
Prevalence of HIV The overall HIV prevalence w males was 14.1% (13.4%-14	vas 14.3% (13.6% 1.9%) and amon	-15.1%) (Table 4). The prev g females 25.0% (16.6%-3	valence of HIV amo 35.1%) (p=0.01). T
Prevalence of HIV The overall HIV prevalence w males was 14.1% (13.4%-14 prevalence of HIV among a	vas 14.3% (13.6% 1.9%) and amon dults and juvenil	-15.1%) (Table 4). The prev g females 25.0% (16.6%-3 les was 15.0% (14.1%-15.7	valence of HIV amc 35.1%) (p=0.01). T 7%) and 3.9% (2.3
Prevalence of HIV The overall HIV prevalence w males was 14.1% (13.4%-14 prevalence of HIV among a 6.2%) (p<0.01) respectively.	vas 14.3% (13.6% 4.9%) and amon dults and juvenil There was no sta	-15.1%) (Table 4). The prev g females 25.0% (16.6%-3 les was 15.0% (14.1%-15. atistically significant differe	valence of HIV amo 35.1%) (p=0.01). T 7%) and 3.9% (2.3
* one-sided, 97.5% confidence int <b>Prevalence of HIV</b> The overall HIV prevalence w males was 14.1% (13.4%-14 prevalence of HIV among a 6.2%) (p<0.01) respectively. HIV between residents and r Table 4: Prevalence of HIV	vas 14.3% (13.6% 4.9%) and amon dults and juvenil There was no sta	-15.1%) (Table 4). The prev g females 25.0% (16.6%-3 les was 15.0% (14.1%-15. atistically significant differe	valence of HIV amo 35.1%) (p=0.01). T 7%) and 3.9% (2.3

Overall	1,170/8,1601	14.3 (13.6-15.1)		
	Sex			
Male	1,139/8,061	14.1 (13.4-14.9)	0.00	
Female	23/89	25.8 (17.4-36.2)		
Missing sex	8/10			
	Category of indiv	vidual		
Adults (≥19 years)	1,153/7,727	15.0 (14.1-15.7)	0.00	
Juveniles (<19 years)	17/433	3.9 (2.3- 6.2)		
Entry point <sup>1,2</sup>				
Residents	1,118/7699	14.5(13.7-15.3)	0.06	
New entrants	52/460	11.3 (8.6-14.6)		

218 Abbreviations: CI- Confidence interval, HIV- Human Immunodeficiency virus

219 Residents include those screened through mass screening and those under entry screening as a transfer from

other correctional facility. New incarcerated individuals include those screened under entry screening from the community (police cells).

<sup>1</sup>One hundred and seven (107) participants either opted out of HIV testing or had missing data

223 <sup>2</sup>Three (3) participants had missing entry point, 2 of which also had missing HIV status

224 (\*) one-sided, 97.5% confidence interval.

225 \*\* not determined.226

# **DISCUSSION**

<sup>19</sup> 228 **Statement of principal findings** 

229 This study found that in Zambian correctional facilities, the prevalence of all forms of TB,

J.E.Z.O,

230 bacteriologically confirmed TB and DR TB were 3.5 times higher, 1.7 times higher and almost

twice as high as in the general population, respectively. (14, 15) Additionally, the prevalence

of HIV was 1.3 times higher than the prevalence in the general population (16). 28.7% of the

233 bacteriologically confirmed TB cases were asymptomatic.

# 234 Study findings in relation to other studies

Page 15 of 25

#### **BMJ** Open

It is noteworthy that there is no statistically significant difference in prevalence of all forms TB and bacteriologically confirmed TB between juveniles and adults and that in fact the point estimates for TB in juveniles were higher; generally older adults have a higher TB burden than adolescents and young adults. (17, 18) This suggests that the disproportionate access to TB services and health services in general among juveniles in Zambian correctional facilities reported between 2009-2010 have persisted. (19) Another significant contrast relative to the general population is the absence of a statistically significant difference in prevalence of bacteriologically confirmed TB between males and females. (15) This could be due to absence of gender related differences in exposure to risk factors for TB infection and disease but could also be due to the small sample size and very wide confidence intervals among females. In comparison to the 2010-2011 study, the prevalence of all forms of TB has reduced by about

75% while the prevalence of bacteriologically confirmed TB has reduced by 50%. (6) The reduction in prevalence of all forms of TB and bacteriologically confirmed TB could be a result of the TB control interventions being implemented within the Zambian correctional facilities. However, it could also be in part because the correctional facilities in the two studies are not the same and the variations in the sensitivity of screening algorithms as a more sensitive algorithm involving x-ray and culture(20, 21) for all inmates was used in the previous study. An observational and modelling study done in Brazil supports the hypothesis of effectiveness of TB control interventions being implemented: entry screening, active screening for TB among inmates, TB preventive therapy and annual mass screening independently reduce the incidence of TB in correctional facilities by 10.3%, 35%, 23.5% and 47.5% respectively after a period of 10 years and a combination of these interventions reduces the TB incidence by 79.2% after a period of 10 years. (22). Other countries in sub-Saharan Africa with results 

 $1^{\cdot}$ 

**BMJ** Open

involving multiple correctional facilities report TB prevalence ranging from 457 - 888 per
100,000 population. (23-25) However, a direct comparison to the prevalence reported in the
other countries can't be done due to differences in definitions of TB used.

The prevalence of DR TB among people with no history of TB is similar to the prevalence among people with previous history of TB, suggesting significant transmission of DR TB either in correctional facilities or in the communities where the incarcerated people come from, or both. Strengthening TB infection control can reduce transmission of DR TB. (26) In comparison to the 2010-2011 study, the prevalence of DR TB has increased by 4%. (6) The increasing trend of DR TB in the Zambian correctional facility setting is also seen at the global and national levels.(27) The prevalence of DR TB in this study can't be directly compared to other correctional facility settings since the forms of drug resistance reported are different. (28-30)

Similar to the national picture, the prevalence of HIV was higher among adults than juveniles and was higher among females than males. (16) However, the prevalence of HIV in women relative to the prevalence of HIV in men is much higher in the incarcerated population than the general population because women with HIV risk factors like sex worker status, intimate partner violence, drug and substance abuse are overrepresented in this population. (31) Despite the very high rates of HIV in this group, relative to the study done by Simooya et al in 1999 which showed a prevalence of 33% in females, the prevalence of HIV has reduced.(32) There has been an 8.6% reduction in overall prevalence of HIV since the study in 2010-2011. (6) The reduction in prevalence of HIV in correctional facilities is attributable to the reduction of HIV prevalence in the general population (16), the implementation of test and treat across Zambia(33), entry HIV testing and treatment(6) and use of correctional health committees to

1 2

#### **BMJ** Open

2	
4	
د د	
5 6 7	
7	
0	
9 10 11 12 13 14 15 16 17 18	
10	
11	
12	
13	
11	
14	
10	
10	
17	
18	
19 20 21	
20	
21	
22	
23	
24	
25	
25 26 27	
20	
27	
28	
29	
30	
31	
32	
33	
34 35 36	
35	
36	
37	
37 38	
30 39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
49 50	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	
OU	

strengthen TB/HIV service delivery at facility level(9). Among African countries with studies
involving several correctional facilities, Zambia's prevalence is lower than South Africa's (25)
but higher than Burkina Faso and Uganda.

287 The difference in prevalence of TB and HIV between residents and new entrants into 288 correctional facilities was not statistically significant. This is possibly due to the following 289 reasons: a) individuals entering correctional facilities come from socio-economically 290 disadvantaged backgrounds where prevalence of TB and HIV are already high (1); b) there are 291 high rates of recidivism (34); and c) detainees spend long periods in police cells, which have 292 similar conditions to the correctional facilities (35, 36). However, the small sample size and wide confidence intervals especially for the new entrants is a limiting factor for drawing any 293 294 inferences from this comparison.

# 295 Strengths and limitations

296 This study provides the most recent evidence on prevalence of TB and HIV in Zambian 297 correctional facilities. The results of this study are generalizable to the 13 correctional 298 facilities, as a large sample representing 85% and 84% of the correctional facility population, 299 was screened for TB and HIV respectively. By virtue of the data being disaggregated, it 300 provides an opportunity for targeting of interventions that can reduce the burden of both 301 diseases. However, there were variations in the strength of screening algorithms for TB, hence 302 the prevalence of TB could have been underestimated in some correctional facilities. That 303 said, among all forms TB cases, it is possible that some of the clinically diagnosed TB cases 304 might not be true TB cases as there are other differential causes of chest x-ray abnormalities 305 that mimic TB. Inmates in court or on the farms were not screened for TB which could have

introduced bias during data collection. Additionally, asymptomatic TB was not consistentlyscreened for.

# 309 CONCLUSION

Despite significant progress over the last decade in controlling TB and HIV in Zambian correctional facilities, these continue to be disproportionately affected by both diseases. TB/HIV programs in correctional facilities need further strengthening including aspects of juvenile specific TB programming and gender responsive HIV programming. Additionally, there is need to consider use of more sensitive algorithms that include chest x-ray to minimize the risk of missing asymptomatic TB cases. Additional studies are required to determine the true prevalence of asymptomatic TB in correctional facilities, to better understand the reason for high HIV burden among females in correctional facilities and to determine the prevalence of TB and HIV using a sample whose results can be generalized to all the correctional facilities in Zambia.

320 ETHICS STATEMENT

Approval to use the programmatic data was obtained from the University of Zambia Biomedical Research Ethics Committee No: 018-11-18 and the London School of Hygiene and Tropical Medicine Ethics Committee No: 21332. Since data was collected under programmatic conditions, no consent was sought for TB screening and verbal consent and assent were obtained for HIV testing. The EJJOH project had obtained permission from the Zambia Correctional service and the Ministry of Community Development and Social services to


1		
2		
3	327	conduct the screening activities including testing of juveniles. When migrating data from the
4 5		
6	328	paper-based registers to the electronic database, participant identifying information was
7		
8	329	excluded.
9		
10		
11 12		
12 13	330	REFERENCES
14	331	1. World Health Organization. Tuberculosis in Prisons [cited 2020 20th July 2020]. Available
15	332	<ol> <li>World Health Organization. Tuberculosis in Prisons [cited 2020 20th July 2020]. Available from: https://www.who.int/tb/areas-of-work/population-groups/prisons-facts/en/.</li> </ol>
16	333	<ol> <li>Telisinghe L, Charalambous S, Topp SM, Herce ME, Hoffmann CJ, Barron P, et al. HIV and</li> </ol>
17	334	tuberculosis in prisons in sub-Saharan Africa. The Lancet. 2016;388(10050):1215-27.
18	335	3. Dolan K, Wirtz AL, Moazen B, Ndeffo-Mbah M, Galvani A, Kinner SA, et al. Global burden of
19 20	336	HIV, viral hepatitis, and tuberculosis in prisoners and detainees. The Lancet. 2016;388(10049):1089-
20 21	337	102.
22	338	4. Reid SE, Topp SM, Turnbull ER, Hatwiinda S, Harris JB, Maggard KR, et al. Tuberculosis and
23	339	HIV control in sub-Saharan African prisons: "thinking outside the prison cell". Journal of Infectious
24	340	Diseases. 2012;205(suppl_2):S265-S73.
25	341	5. World Health Organization Regional Office for Europe. Prisons and health. Copenhagen,
26	342	Denmark2014. 45-70, 83 p.
27 28	343	6. Maggard KR, Hatwiinda S, Harris JB, Phiri W, Krüüner A, Kaunda K, et al. Screening for
28 29	344	tuberculosis and testing for human immunodeficiency virus in Zambian prisons. Bulletin of the World
30	345	Health Organization. 2015;93:93-101.
31	346	7. Ubumi Prisons Iniative. Zambian Prisons [updated 4th August 2020; cited 2020 4th August
32	347	2020]. Available from: <u>https://ubumi.net/zambian_prisons.html</u> .
33	348	8. Herce ME, Hoffmann CJ, Fielding K, Topp SM, Hausler H, Chimoyi L, et al. Universal test-and-
34	349	treat in Zambian and South African correctional facilities: a multisite prospective cohort study. The
35	350	Lancet HIV. 2020;7(12):e807-e16.
36 37	351	9. Topp SM, Sharma A, Moonga CN, Chileshe C, Magwende G, Henostroza G. Evaluation of a
38	352	health system strengthening initiative in the Zambian prison system. BMJ global health. 2018;3(1).
39	353	10. Herce ME, Muyoyeta M, Topp SM, Henostroza G, Reid SE. Coordinating the prevention,
40	354	treatment, and care continuum for HIV-associated tuberculosis in prisons: a health systems
41	355	strengthening approach. Current Opinion in HIV and AIDS. 2018;13(6):492.
42	356	11. Institute of Crime and Justice Policy Research B. World Prison Brief 2020 [cited 2020 21st
43	357	July 2020]. Available from: <u>https://www.prisonstudies.org/country/zambia</u> .
44 45	358	12. Government of the Republic of Zambia. The Juvenile Act. Chapter 53 of the Laws of
45 46	359	Zambia1964.
47	360	13. Government of the Republic of Zambia. The Prisons Act Lusaka, Zambia: Government
48	361	Printer; 2004 [cited 2020 13th May 2020]. Available from:
49	362	https://www.parliament.gov.zm/node/840.
50	363	14. Kapata N, Mbulo G, Cobelens F, de Haas P, Schaap A, Mwamba P, et al. The second Zambian
51	364	national tuberculosis drug resistance survey–a comparison of conventional and molecular methods.
52	365	Tropical Medicine & International Health. 2015;20(11):1492-500.
53 54	366	15. Kapata N, Chanda-Kapata P, Ngosa W, Metitiri M, Klinkenberg E, Kalisvaart N, et al. The
54 55	367	prevalence of tuberculosis in Zambia: results from the first national TB prevalence survey, 2013–
56	368	2014. PLoS One. 2016;11(1):e0146392.
57	369	16. Ministry of Health Zambia. Zambia Population-based HIV Impact assessment 2016. Lusaka;
58	370	2019.
59	371	17. Donald PR, Marais BJ, Barry CE. Age and the epidemiology and pathogenesis of tuberculosis.
60	372	The Lancet. 2010;375(9729):1852-4.


18. Stop TB partnership. Tuberculosis Situation in 2019, Zambia [cited 2021 19th February 2021]. Available from: http://stoptb.org/resources/cd/ZMB\_Dashboard.html. 19. Todrys KW, Amon JJ. Human rights and health among juvenile prisoners in Zambia. Int J Prison Health. 2011;7(1):10-7. 20. World Health Organisation. Chest Radiography in Tuberculosis Case Detection. Switzerland2016 [cited 2021 10th June 2021]. Available from: https://apps.who.int/iris/bitstream/handle/10665/252424/9789241511506-eng.pdf;jsessionid=72EC9D02021FEBF4C6CCA41896818F45?sequence=1. World Health Organisation. WHO operational handbook on TB diagnosis. Geneva2020 [cited 21. 2021 1oth June 2021]. Available from: https://www.who.int/publications/i/item/who-operational-handbook-on-tuberculosis-module-3-diagnosis---rapid-diagnostics-for-tuberculosis-detection. 22. Mabud TS, de Lourdes Delgado Alves M, Ko AI, Basu S, Walter KS, Cohen T, et al. Evaluating strategies for control of tuberculosis in prisons and prevention of spillover into communities: An observational and modeling study from Brazil. PLoS medicine. 2019;16(1):e1002737. 23. Melese A, Demelash H. The prevalence of tuberculosis among prisoners in Ethiopia: a systematic review and meta-analysis of published studies. Archives of Public Health. 2017;75(1):1-9. 24. Banda H, Gausi F, Harries A, Salaniponi F. Prevalence of smear-positive pulmonary tuberculosis among prisoners in Malawi: a national survey. The international journal of tuberculosis and lung disease. 2009;13(12):1557-9. Stevenson KA, Podewils LJ, Zishiri VK, Castro KG, Charalambous S. HIV prevalence and the 25. cascade of care in five South African correctional facilities. PLoS One. 2020;15(7):e0235178. 26. Organization WH. WHO policy on TB infection control in health-care facilities, congregate settings and households. World Health Organization; 2009. Report No.: 9241598328. World health Organisation. Global Tuberculosis Report 2019 2019 [Available from: 27. https://apps.who.int/iris/bitstream/handle/10665/329368/9789241565714-eng.pdf?ua=1. Gizachew Beza M, Hunegnaw E, Tiruneh M. Prevalence and associated factors of 28. tuberculosis in prisons settings of East Gojjam Zone, Northwest Ethiopia. International journal of bacteriology. 2017;2017. 29. Séri B, Koffi A, Danel C, Ouassa T, Blehoué M-A, Ouattara E, et al. Prevalence of pulmonary tuberculosis among prison inmates: A cross-sectional survey at the Correctional and Detention Facility of Abidjan, Côte d'Ivoire. PloS one. 2017;12(7):e0181995. Noeske J, Ndi N, Mbondi S. Controlling tuberculosis in prisons against confinement 30. conditions: a lost case? Experience from Cameroon. The International journal of tuberculosis and lung disease. 2011;15(2):223-7. 31. United Nations Office on Drug and Crime U. Women and HIV in prison settings Austria2008 [cited 2021 1st February 2021]. Available from: https://www.unodc.org/documents/middleeastandnorthafrica/drug-prevention-health-publications/WOMEN AND HIV IN PRISON SETTINGS.pdf. 32. Simooya OO, Sanjobo NE, Kaetano L, Sijumbila G, Munkonze FH, Tailoka F, et al. 'Behind walls': a study of HIV risk behaviours and seroprevalence in prisons in Zambia. Aids. 2001;15(13):1741-4. 33. Zambia MoH. Zambia Consolidated Guidelines on Treatment and Prevention of HIV infection. Lusaka; 2016. Yukhnenko D, Sridhar S, Fazel S. A systematic review of criminal recidivism rates worldwide: 34. 3-year update. Wellcome open research. 2019;4. Henostroza G, Topp SM, Hatwiinda S, Maggard KR, Phiri W, Harris JB, et al. The high burden 35. of tuberculosis (TB) and human immunodeficiency virus (HIV) in a large Zambian prison: a public health alert. PloS one. 2013;8(8):e67338. Todrys KW, Amon JJ, Malembeka G, Clayton M. Imprisoned and imperiled: access to HIV and 36. TB prevention and treatment, and denial of human rights, in Zambian prisons. Journal of the International AIDS Society. 2011;14(1):1-11. 

1 2		
3 4	424	
5 6 7 8	425	ACKNOWLEDGEMENT
9 10 11	426	The Zambia Correctional Service, Ministry of Community Development and Social Welfare and
12 13	427	the correctional health committees are acknowledged for the support provided to the EJJOH
14 15 16	428	project team during data collection. Innocent Mwaba is acknowledged for drawing the map
17 18	429	showing study sites.
19 20 21	430	
22 23 24 25 26	431	FUNDING
27 28 29	432	This research was funded by the Elton John AIDS Foundation; under the Elton John Juveniles
30 31	433	Offenders' Health (EJJOH) project (no grant number received).
32 33 34 35	434	
36 37 38	435	AUTHOR CONTRIBUTIONS
39 40 41		
42 43	436	Conceived and designed the study: MK, SH, CNM, MM. Database design and data curation:
44 45	437	PS, JB. Implemented the study: MK, SH, MT, TZ, CNM, MM. Data analysis: PS, MK, FB. Wrote
46 47 48	438	the original draft: MK. Reviewed the manuscript: SH, MT, JB, PS, TZ, FB, CNM, MM. Approved
49 50 51	439	the final version to be published: MK, SH, PS, MT, JB, TZ, FB, CNM, MM.
52 53	440	The corresponding author attests that all listed authors meet authorship criteria and that no
54 55 56 57 58 59 60	441	others meeting the criteria have been omitted.

1 2 3 4 5 6 7 8	442	
9 10 11	443	CONFLICT OF INTEREST
12 13 14	444	The authors declare no conflict of interest.
15 16 17	445	
18 19		
20 21 22	446	DATA SHARING STATEMENT
23 24 25	447	Additional data is available upon request by emailing Monde.Muyoyeta@cidrz.org
26 27		
28		
29 30		
31		
32 33		
34		
35 36		
37		
38 39		
40		
41 42		
43		
44 45		
46		
47 48		
49 50		
51		
52 53		
54		
55 56		
57		
58 59		
60		

Page 23 of 25







HIV- Human Immunodeficiency Virus, TB- Tuberculosis

\*All symptomatic patients submitted sputum, however, some correctional facilities only documented results of patients with positive results.

N





	Item No	Recommendation	Pag No
Title and abstract	1	( <i>a</i> ) Indicate the study's design with a commonly used term in the title or the abstract	2
		( <i>b</i> ) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any prespecified hypotheses	4
Methods			
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5,6
Participants	6	( <i>a</i> ) Give the eligibility criteria, and the sources and methods of selection of participants	6,7
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7,8
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6,7
Bias	9	Describe any efforts to address potential sources of bias	6
Study size	10	Explain how the study size was arrived at	6
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	7,8
Statistical methods	12	( <i>a</i> ) Describe all statistical methods, including those used to control for confounding	7,8
		(b) Describe any methods used to examine subgroups and interactions	7,8
		(c) Explain how missing data were addressed	8
		( <i>d</i> ) If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	8,9
		(b) Give reasons for non-participation at each stage	8,9
		(c) Consider use of a flow diagram	9
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	9,1
		(b) Indicate number of participants with missing data for each variable of interest	10- 13
Outcome data	15*	Report numbers of outcome events or summary measures	10

Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted	
		estimates and their precision (eg, 95% confidence interval). Make clear	
		which confounders were adjusted for and why they were included	
		(b) Report category boundaries when continuous variables were	10
		categorized	13
		( <i>c</i> ) If relevant, consider translating estimates of relative risk into absolute	
		risk for a meaningful time period	
Other analyses	17	Report other analyses done-eg analyses of subgroups and interactions,	10
		and sensitivity analyses	13
Discussion			
Key results	18	Summarise key results with reference to study objectives	13
Limitations	19	Discuss limitations of the study, taking into account sources of potential	16
		bias or imprecision. Discuss both direction and magnitude of any potential	
		bias	
Interpretation	20	Give a cautious overall interpretation of results considering objectives,	13
		limitations, multiplicity of analyses, results from similar studies, and other	16
		relevant evidence	
Generalisability	21	Discuss the generalisability (external validity) of the study results	16
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study	20
		and, if applicable, for the original study on which the present article is	
		based	

\*Give information separately for exposed and unexposed groups.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.

**BMJ** Open

# **BMJ Open**

## A cross sectional assessment of Tuberculosis and Human Immunodeficiency Virus prevalence in 13 correctional facilities in Zambia

Journal:	BMJ Open	
Manuscript ID	bmjopen-2021-052221.R2	
Article Type:	Original research	
Date Submitted by the Author:	15-Aug-2021	
Complete List of Authors:	Kagujje, Mary; Center for Infectious Disease Research in Zambia, Tuberculosis department Somwe, Paul; Center for Infectious Disease Research in Zambia, Strategic Information department Hatwiinda, Sisa; Center for Infectious Disease Research in Zambia, Tuberculosis department Bwalya, Joel; Center for Infectious Disease Research in Zambia, Strategic Information department Zgambo, Tamala; Zambia Correctional Service Thornicroft, Moomba; Center for Infectious Disease Research in Zambia, Tuberculosis department Bozzani, Fiammetta; London School of Hygiene and Tropical Medicine Faculty of Public Health and Policy Moonga, Clement; Center for Infectious Disease Research in Zambia Muyoyeta, Monde ; Center for Infectious Disease Research in Zambia	
<b>Primary Subject Heading</b> :	Epidemiology	
Secondary Subject Heading:	Infectious diseases, Public health	
Keywords:	Tuberculosis < INFECTIOUS DISEASES, HIV & AIDS < INFECTIOUS DISEASES, EPIDEMIOLOGY, PUBLIC HEALTH	

# SCHOLARONE<sup>™</sup> Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

reliez oni

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

3	
4	
5	
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
22	
24 25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
40 49	
49 50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	
00	

1	A cross sectional assessment of Tuberculosis and Human
2	Immunodeficiency Virus prevalence in 13 correctional
3	facilities in Zambia
4	
5	Mary Kagujje (0000-0003-4818-6548) <sup>1</sup> , Paul Somwe <sup>2</sup> , Sisa Hatwiinda <sup>1</sup> , Joel Bwalya <sup>2</sup> , Tamala

6	Zgamb	oo <sup>3</sup> , Moomba Thornicroft <sup>1</sup> , Fiammetta Bozzani <sup>4</sup> , Clement Nchimunya Moonga <sup>1</sup> , Monde
7	Muyoy	yeta <sup>1</sup>
8	Autho	r affiliations
9	1.	Tuberculosis department, Centre for Infectious Disease Research in Zambia, P.O. Box 34681
10		Lusaka, Zambia 10101
11	2.	Strategic Information department, Centre for Infectious Disease Research in Zambia, P.O. Box
12		34681 Lusaka, Zambia 10101
13	3.	Zambia Correctional Service, P.O. Box 80926 Kabwe, Zambia 10101
14	4.	London School of Hygiene and Tropical Medicine, Keppel Street London WCIE 7HT, United
15		Kingdom
16		
17	Corres	spondence to Mary Kagujje; <u>mkagujje@gmail.com</u>
18		

19	Key words: Correctional facilities	, Tuberculosis, HIV	/, incarcerated population	, Zambia
17	itey words. correctional facilities		, mearceratea population	, Lambia

#### ABSTRACT

**Objective:** To determine the prevalence of Tuberculosis (TB) and Human Immunodeficiency

- virus (HIV) in 13 Zambian correctional facilities.
- Methods: Cross sectional study
- Setting: 13 correctional facilities in 7 of the 10 provinces in Zambia.

Participants: All incarcerated individuals were eligible for TB and HIV screening and testing.

Of the total study population of 9,695 individuals, which represent 46.2% of total correctional

population at the beginning of the study, 8,267 and 8,160 were screened for TB and HIV 

respectively.

Interventions: TB and HIV screening and testing was done between July 2018 and February 2019. 

Primary outcome measures: All forms of TB, bacteriologically confirmed TB, drug resistant TB, HIV

Results: Prevalence of all forms of TB and bacteriologically confirmed TB was 1598(1340-

1894) per 100,000 population and 1056(847-1301) per 100,000 population, respectively.

Among those with bacteriologically confirmed TB, 4.6% (1.3%-11.4%) had drug resistant TB. 

There was no statistically significant difference in the prevalence of different forms of TB between adults and juveniles: (p= 0.82), (p= 0.23), (p=0.68). Of the bacteriologically confirmed TB cases, 28.7% were asymptomatic. The prevalence of HIV was 14.3% (13.6%-15.1%). The prevalence of HIV among females was 1.8 times the prevalence of HIV among males (p=0.01).

**Conclusion:** Compared to the study in 2011 which screened inmates representing 30% of the country's inmate population then, the prevalence of all forms of TB and HIV in correctional 

facilities has reduced by about 75% and 37.6% respectively. However, compared to the general population, the prevalence of all forms of TB and HIV was 3.5 and 1.3 times higher, respectively. TB/HIV programs in correctional facilities need further strengthening to include

aspects of juvenile specific TB programming and gender responsive HIV programming.

<text>

1 2 3		
4 5 6 7	49	ARTICLE SUMMARY
8 9 10	50	Strengths and limitations of this study
11 12	51	• This is the only study on prevalence of TB and HIV in Zambian correctional facilities in the
13 14 15	52	past 8 years.
16 17	53	Results are generalisable to the 13 correctional facilities as a large sample was screened
18 19	54	for TB and HIV.
20 21 22	55	Data disaggregates can inform targeted interventions to reduce the burden of both
23 24	56	diseases.
25 26 27	57	Variations in TB screening algorithms could have underestimated TB prevalence.
28 29	58	Asymptomatic TB was not consistently screened for.
$\begin{array}{c} 30\\ 31\\ 32\\ 33\\ 34\\ 35\\ 36\\ 37\\ 38\\ 39\\ 40\\ 41\\ 42\\ 43\\ 44\\ 45\\ 46\\ 47\\ 48\\ 49\\ 50\\ 51\\ 52\\ 53\\ 54\\ 55\\ 56\\ 57\\ 58\\ 59\\ 60\\ \end{array}$	59	

# 60 INTRODUCTION

Globally, correctional facilities are disproportionately affected by tuberculosis (TB) and the Human Immunodeficiency Virus (HIV). (1-3) In some correctional facilities: the prevalence of TB has been reported to be up to 100 times higher than the prevalence in the general population (1) while the prevalence of HIV has been reported to be up to 23 times higher than the prevalence in the general population(3). The poor living conditions in correctional facilities perpetuate TB and HIV. While overcrowding, poor ventilation, HIV, poor nutrition and late case detection perpetuate TB; sexual violence, sharing of sharp objects and lack of access to condoms perpetuate HIV. (4, 5) Additionally, incarcerated people often come from socio-economically disadvantaged backgrounds where the burden of TB and HIV is already high. (1, 3)

In 2011, the prevalence of all forms of TB in 6 Zambian correctional facilities representing 30% of the total incarcerated population was 6,428 per 100,000 population, which was 18 times higher than the national estimates. (6) In the same study, 0.6% of those with bacteriologically confirmed TB had rifampicin-resistant TB and the overall prevalence of HIV was 22.9%, which was 1.5 times the national prevalence.

Since the last documented prevalence survey, several interventions including test and treat
for HIV, health systems strengthening, nutritional support, TB and HIV entry screening, among
others, have been put in place to control the burden of TB and its associated risk factors in
Zambia correctional facilities. (7-10)

 This study aimed to determine current prevalence of all forms of TB, bacteriologically
confirmed TB, and drug resistant (DR) TB and the prevalence of HIV in 13 Zambian correctional
facilities.

# **METHODS**

## 87 Study design

We present an analysis of cross-sectional data collected under programmatic conditions by the Elton John Juvenile Offenders' health (EJJOH) project. The EJJOH project was a health system strengthening project aimed at supporting provision of holistic and integrated health services to juvenile offenders. While the project primarily targeted juveniles, its support was extended to adults being held in the same facility with the juveniles so as to improve infectious disease control. The project screened the incarcerated population as part of its baseline assessment.

95 Study setting and population

2ambia has 87 correctional facilities with a total capacity of 9,150 incarcerated individuals.
(11) However, the total incarcerated population in Zambia was slightly over 21,000 in 2018
and 22,823 in 2019. In 2019, almost one in five individuals detained was in pre-trial detention.
(11) The data was collected between July 2018 and February 2019 in 13 correctional facilities
with a combined population of 9,695, representing 46.2% of the total correctional facility
population in Zambia in 2018. The 13 correctional facilities had been purposefully selected by
the EJJOH project because they held a significant number of juveniles. The facilities include

#### **BMJ** Open

Lusaka Central, Kamwala Remand, Livingstone Central, Katombora Reformatory School, Nakambala Approved school, Mukobeko Medium, Ndola remand, Kamfinsa State, Chingola, Insakwe Approved School, Chipata Central, Mongu Central and Kasama Central (locations shown in Supplementary Figure 1). The Reformatory and approved schools hold ordered (convicted) juveniles (persons less than 19 years old)(12); the other facilities are intended only for adults and circumstantial children(13) but also hold juveniles who are still undergoing trial. Across Zambia, routinely, incarcerated people should undergo universal TB screening and HIV testing at entry or within 7 days of admission into correctional facilities. However, in some facilities entry screening is not done due to various constraints. Depending on availability of logistics, periodic TB and HIV mass screening are carried out, with freedom to opt out of HIV testing but not TB screening and testing. TB screening is mandatory to increase early TB detection and treatment so as to protect other inmates from TB.

## 118 Study Procedures

A project specific register was used; it was a modification of the National Presumptive TB register with additional data elements on entry point, category of individual and previous history of TB. All inmates were screened for TB; those who did not opt out were tested for HIV. The screening point was documented under one of the following categories: mass screening, entry screening from the community or entry screening transfer from other correctional facility. The categories of individuals included adults and juveniles. Those already on anti-TB treatment at the time of screening were documented as TB cases and those on

#### **BMJ** Open

anti-retroviral therapy (ART) were recorded as HIV positive and were not retested. Those with cough, fever, weight loss, night sweats, chest pain and shortness of breath, irrespective of duration, were considered presumptive TB patients and submitted sputum for testing using GeneXpert (Xpert MTB/Rif Assay. Cepheid, Sunnyvale, California, USA). Symptomatic individuals with a negative GeneXpert were referred for Chest x-ray (CXR) depending on the clinician's discretion. There were 3 variations to this algorithm: 1) In Lusaka central, a random proportion of the incarcerated population received CXR in addition to symptoms screening and those with either abnormal CXR or symptoms submitted sputum for GeneXpert; 2) at Ndola remand, all except those already on TB treatment submitted sputum irrespective of symptoms; and 3) in Kabwe medium, Fluorescent Microscopy (FM) was used for sputum examination instead of GeneXpert. 

Alere Determine<sup>™</sup> HIV-1/2 test (AlereHIV-1/2; Abbott, Chicago, IL, USA) was used for HIV
screening and SD-Bioline HIV-1/2 (SD-Bioline HIV-1/2; Abbott, Chicago, IL, USA) for
confirmation of positive screening test, following the standard Zambian HIV testing algorithm.
All individuals received pre- and post-test HIV counselling. HIV positive inmates were
commenced on ART within 1-2 days.

## 143 Data analysis

STATA Statistical Software (Stata Corporation Version 14. College Station, Texas 77845, USA)
 was used for data analysis. A descriptive analysis was done to determine the characteristics
 of the population screened and the prevalence of TB and HIV; overall prevalence and
 prevalence among subgroups was determined. The prevalence of all forms of TB included
 bacteriologically confirmed TB and clinically diagnosed TB. Bacteriologically confirmed TB

**BMJ** Open

prevalence included those who had a positive GeneXpert or FM result, while patients already
on TB treatment at time of screening were excluded from this analysis since data on the type
of TB had not been collected. DR TB prevalence included incarcerated people with rifampicin
resistance on GeneXpert. Missing data was excluded from the analysis.

Additionally, a chi-square test was done to determine if there was a statistically significant difference in prevalence of TB and HIV between residents and new entrants into correctional facilities. New entrants were defined as incarcerated people whose entry point was entry screening from community while residents were defined as those whose entry point was either mass screening or entry screening transfer from other correctional facility.

**Patient and Public involvement** 

The development of the research questions was intended to inform priority setting by the EJJOH project based on the disease burden in correctional facilities. The incarcerated population were not involved in the design of the project. The correctional health committees constituting of the incarcerated persons, correctional officers and health care workers were involved in the data collection. A representative of the correctional health committee at each correctional facility participated in the dissemination meeting on project findings.

- - **RESULTS**

167 Flow diagram and participant characteristics

#### **BMJ** Open

3
4
5
6
7 8
o 9
10
11
12
13 14
14 15
16 17 18
18
19 20
20 21
22 23 24 25 26 27
24
25
20 27
28
28 29
30
31 32
32 33
34
35
36
37 38
38 39
40
41
42
43
44 45
46
47
48
49
50 51
52
53
54
55
56 57
57 58
59
60

168 Of the total adult and juvenile population of 9,695 in the 13 correctional facilities, 8160 169 (84.2%) were screened for HIV and 8,267(85.3%) were screened for TB (Figure 1). Individuals 170 not screened were 1,428 (14.7%) and they constituted those either in court or the farms. Of 171 those screened for HIV, 1170(14.3%) were HIV positive, of which 816 were known positive 172 and 354 were new positives, while 6,990 (85.7%) were HIV negative. Of those screened for 173 TB, 17(0.2%) were already on treatment, 3,076 (37.3%) individuals had symptoms of TB, 5,161 174 (62.5%) were asymptomatic while 13 (0.2%) had missing data. A total of 4,269 individuals had 175 documented sputum results. Eighty seven (87) bacteriologically confirmed TB cases were 176 reported including 25(28.7%) asymptomatic individuals 62(71.3%) symptomatic individuals. A 177 total of 132 TB cases were identified including 87 (65.9%) bacteriologically confirmed TB 178 cases, 28 (21.2%) clinically diagnosed TB cases and the 17 (12.9%) that were already on TB 179 treatment at the time of screening. 180 Figure 1: Flow diagram of TB screening and diagnosis

, 5 181

> Of those screened, 7,805 (94.41%) were adults and 462 (5.58%) were juveniles (Table 1). The overall median age (interquartile range (IQR)) of the participants was 32 years (IQR 10-93); the median ages for the adults and juveniles were 33(IQR 19-93) and 17(IQR 10-18) respectively. The males were 8,167 (98.79%), participants with a history of previous TB were 467 (5.65%), resident inmates were 7,767 (93.95%) while new entrants were 497 (6.01%).

187 Table 1: Characteristics of population screened

Variable	Participants (n= 8267)	
Category of individual	n (%)	
Adults	7,805 (94.41%)	
Juveniles	462 (5.58%)	

2	
3	
4	
4 5 6	
6	
7	
8	
9	
10	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30	
26	
20	
27	
20	
29	
30	
31 32 33	
32 33	
33	
34 35	
35	
36	
37	
36 37 38	
39	
40	
41	
42	
43	
44	
44 45	
45 46	
40 47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	
00	

Median Age (IQR)	
Overall	32(10-93)
Adults (≥19 years)	33 (19-93)
Juveniles (<19 years)	17 (10-18)
Sex	n (%)
Male	8,167 (98.79%)
Female	89 (1.08%)
Missing	11 (0.13%)
History of previous TB	n (%)
Yes	467 (5.65%)
No	7,786 (94.18%)
Missing	14 (0.17%)
Type of screening visit	n (%)
Mass screening	7,602 (91.92%)
Entry screening other correctional facility	165 (2.00%)
Entry screening community	497 (6.01%)
Missing	3 (0.04%)

# 188 189

#### Prevalence of all forms of TB and bacteriologically confirmed TB 190

191 The overall prevalence of all forms of TB was 1,598 (1339-1892) per 100,000 population while 192 the overall prevalence of bacteriologically confirmed TB was 1,056 (844-1301) per 100,000 193 population (Table 2). There was no statistically significant difference in the prevalence of both 194 all forms of TB and bacteriologically confirmed TB between males and females, (p=0.51) and 195 (p=1.00) respectively. It was the same for adults and juveniles (p=0.82) and (p=0.23)196 respectively and the new entrants and residents (p=0.25) and (p=0.21) respectively.

#### 197 Table 2: Prevalence of all forms of TB and bacteriologically confirmed TB

Cases/ Participants (n/N)	Prevalence of all forms of TB per 100,000 (CI)	p- value	Cases/ Participants (n/N)	Prevalence of Bacteriologically confirmed TB per 100,000 (CI)	p- value
---------------------------------	---	-------------	---------------------------------	--	-------------

	Overall	132/8,2541	1599 (1340-1894)		87/8,237 <sup>1,2</sup>	1056 (847-1301)	
				Sex			
	Male	129/8,154	1582 (1322-1877)	0.60	84/8,137	1032 (824-1276)	0.70
	Female	1/89	1124 (28- 6102)	0.60	1/89	1124 (28- 6102)	_ 0.79
	Missing gender	2/11			2/11		
			Category	of indiv	ridual	I	-1
	Adult (≥19 years)	124/7,792	1591 (1325- 1894)	0.82	79/7,775	1016 (805-1265)	0.23
	Juvenile (<19 years)	8/462	1732 (750-3383)		8/462	1732 (750-3383)	0.25
			Entr	y point <sup>1,</sup>	3		
	Residents	121/ 7757	1560 (1296- 1861)	0.25	79/7740	1020 (809-1270)	0.21
	New entrants	11/494	2227 (1117-3949)	~	8/494	1619 (702-3166)	
98 99 00 01 02 03 04	Abbreviations: CI- Confidence interval, TB- Tuberculosis Residents include those screened through mass screening and those under entry screening as a transfer from other correctional facility. New entrants include those screened under entry screening from the community (police cells). <sup>1</sup> Thirteen (13) participants had missing values on TB. <sup>2</sup> Seventeen participants were already on TB treatment, bacteriological status unknown <sup>3</sup> Three (3) participants had missing values on entry point						
05	Prevalence of DR TB						
06	Among the bacte	riologically conf	irmed TB cases,	, the ove	rall prevalence o	of DR TB was 4.6%	
07	(1.3%-11.4%) (Table 3). There was no statistically significant difference in prevalence of DR TB						
)8	between males a	between males and females (p=0.95), between adults and juveniles (p=0.68), between those					

52 208 between males and females (p=0.95), between adults and juveniles (p=0.68), between those 53

 $^{54}$  209 with and those without previous history of TB (p=0.72) and between the new entrants and

57 210 residents(p=0.26).

59 211 Table 3: Prevalence of drug resistant TB60

2 3 4	
4 5	
5 6 7 8	
8 9	
10	
11 12	
12 13 14 15	
15	
15 16 17 18	
18 19	
20 21	
22	
23 24	
25	
26 27 28	
29	
30 31	
32 33	
34	
35 36	
36 37 38	
39	
40 41	
42 43	
44	
45 46	
47 48	
49 50	
51	
52 53	
54 55	
56	
57 58	
59 60	

		Cases/ Participants (n/N)	Prevalence of DR TB % (CI)	p-value	
	Overall	4/87	4.6 (1.3-11.4)		
		Se	ex		
	Male	4/84	4.8 (1.3-11.7)	0.95	
	Female	0/1	0 (0- 97.5) *		
	Missing	0/2			
		Category of	findividual		
	Adults (≥19 years)	4/79	5.1 (1.4-12.5)	0.68	
	Juveniles (<19 years)	0/8	0 (0-3.7) *		
		Previous Hi	story of TB		
	No	3/64	4.7 (1.0-13.1)	0.72	
	Yes	1/23	4.3 (0.1-21.9)		
		Entry	point		
	Residents	3/76	3.8 (0.8-10.7)	0.26	
	New entrants	1/8	12.5 (0.3-52.7)		
212 213 214 215 216 217	<ul> <li>Residents include those screened through mass screening and those under entry screening as a transfer from</li> <li>other correctional facility.</li> <li>New incarcerated individuals include those screened under entry screening from the community (police cells).</li> <li>* one-sided, 97.5% confidence interval</li> </ul>				
218	Prevalence of HIV				
219	The overall HIV prevalence was 14.3% (13.6%-15.1%) (Table 4). The prevalence of HIV among				
220	males was 14.1% (13.4%-14	.9%) and among	g females 25.8% (16.6%-3	85.1%) (p=0.01). The	
221	prevalence of HIV among adults and juveniles was 15.0% (14.1%-15.7%) and 3.9% (2.3%-				
222	6.2%) (p<0.01) respectively. There was no statistically significant differences in prevalence of				

HIV between residents and new entrants (*p*=0.05).

224 Table 4: Prevalence of HIV

Cases/ Partie (n/N)	ipants Prevalence of HIV p-val % (CI)	lue
------------------------	--	-----

Overall	1,170/8,1601	14.3 (13.6-15.1)	
	Sex		
Male	1,139/8,061	14.1 (13.4-14.9)	0.00
Female	23/89	25.8 (17.4-36.2)	
Missing sex	8/10		
Category of individual			
Adults (≥19 years)	1,153/7,727	15.0 (14.1-15.7)	0.00
Juveniles (<19 years)	17/433	3.9 (2.3- 6.2)	
Entry point <sup>1,2</sup>			
Residents	1,118/7699	14.5(13.7-15.3)	0.06
New entrants	52/460	11.3 (8.6-14.6)	

225 Abbreviations: CI- Confidence interval, HIV- Human Immunodeficiency virus

Residents include those screened through mass screening and those under entry screening as a transfer from other correctional facility. New incarcerated individuals include those screened under entry screening from the community (police cells).

7.CZ

<sup>1</sup>One hundred and seven (107) participants either opted out of HIV testing or had missing data

230 <sup>2</sup>Three (3) participants had missing entry point, 2 of which also had missing HIV status

231 (\*) one-sided, 97.5% confidence interval.

\*\* not determined.

# **DISCUSSION**

<sup>39</sup> 235 **Statement of principal findings** 

This study found that in Zambian correctional facilities, the prevalence of all forms of TB, bacteriologically confirmed TB and DR TB were 3.5 times higher(14), 1.7 times higher(14) and 3.5 times higher(15) than the respective prevalence in the general population. Additionally, the overall prevalence of HIV was 1.3 times higher than the prevalence in the general population (16) and the prevalence of HIV among females was 1.8 times higher than the prevalence of HIV among males within correctional facilities. Of the bacteriologically confirmed TB cases, 28.7% were asymptomatic.

1	
2 3 4	2
3 4 5 6 7 8 9 10	2
, 8 9	2
11	2
12 13 14 15 16	2
14 15 16 17	2
17 18 19	2
20 21	2
20 21 22 23 24 25 26 27 28 29	2
25 26	2
27 28 20	2
30 31	2
32 33	2
34 35 36	2
36 37 38	2
39 40 41	2
42 43	2
44 45 46	2
47 48	2
49 50 51	2
51 52 53	2
54 55	2
56 57 58	2
59 60	2

#### Study findings in relation to other studies 43

44 It is noteworthy that there is no statistically significant difference in prevalence of all forms 45 TB and bacteriologically confirmed TB between juveniles and adults and that in fact the point 46 estimates for TB in juveniles were higher; generally older adults have a higher TB burden than 47 adolescents. (17, 18) This suggests that the disproportionate access to TB services and health 48 services in general among juveniles in Zambian correctional facilities reported between 2009-.49 2010 has persisted. (19) Another significant contrast relative to the general population is the 50 absence of a statistically significant difference in prevalence of bacteriologically confirmed TB 51 between males and females. (14) This could be due to absence of gender related differences 52 in exposure to risk factors for TB infection and disease but could also be due to the small 53 sample size and very wide confidence intervals among females.

54

55 In comparison to the 2010-2011 study, the prevalence of all forms of TB has reduced by about 56 75% while the prevalence of bacteriologically confirmed TB has reduced by 50%. (6) The 57 reduction in prevalence of all forms of TB and bacteriologically confirmed TB could be a result 58 of the TB interventions being implemented within the Zambian correctional facilities since 59 2011. This explanation is supported by findings from an observational and modelling study 60 done in Brazil: entry screening, active screening for TB among inmates, TB preventive therapy 61 and annual mass screening independently reduce the incidence of TB in correctional facilities 62 by 10.3%, 35%, 23.5% and 47.5% respectively after a period of 10 years and a combination of 63 these interventions reduces the TB incidence by 79.2% after a period of 10 years. (20) However, it is worth mentioning that though the previous study used a more sensitive 64 65 algorithm involving x-ray and culture(21, 22) for all inmates, the reduction is so large that it 66 cannot simply be explained by use of different algorithms. Other countries in sub-Saharan

**BMJ** Open

2		
3 4	267	Africa with results involving multiple correctional facilities report TB prevalence ranging from
5 6 7	268	457 - 888 per 100,000 population. (23-25) However, a direct comparison to the prevalence
7 8 9	269	reported in the other countries can't be done due to differences in definitions of TB used and
10 11	270	differences in prevalence in the general population.
12 13	271	
14 15 16	272	The prevalence of DR TB among people with no history of TB is similar to the prevalence
17 18	273	among people with previous history of TB, suggesting significant transmission of DR TB either
19 20 21	274	in correctional facilities or in the communities where the incarcerated people come from, or
22 23	275	both. Strengthening TB infection control can reduce transmission of DR TB. (26) In comparison
24 25 26	276	to the 2010-2011 study, the prevalence of DR TB has increased by 667%. (6) The increasing
27 28	277	trend of DR TB in the Zambian correctional facility setting is also seen at the global and
29 30 31	278	national levels.(27) The prevalence of DR TB in this study can't be directly compared to other
31 32 33	279	correctional facility settings since the forms of drug resistance reported are different. (28-30)
34 35	280	
36 37 38	281	Similar to the national picture, the prevalence of HIV was higher among adults than juveniles
39 40	282	and was higher among females than males. (16) However, the prevalence of HIV in women
41 42 43	283	relative to the prevalence of HIV in men is much higher in the incarcerated population than
44 45	284	the general population because women with HIV risk factors like sex worker status, intimate
46 47 48	285	partner violence, drug and substance abuse are overrepresented in this population. (31)
48 49 50	286	Additionally, women are exposed to sexual abuse while in custody and they have more access
51 52	287	barriers to HIV prevention, testing and treatment services compared to men. (32) Despite the
53 54 55	288	very high rates of HIV in this group, relative to the study done by Simooya et al in 1999 which
56 57	289	showed a prevalence of 33% in females, the prevalence of HIV has reduced.(33) There has
58 59 60	290	been a 37.6% reduction in overall prevalence of HIV since the study in 2010-2011. (6) The

#### **BMJ** Open

reduction in prevalence of HIV in correctional facilities is attributable to the reduction of HIV prevalence in the general population(16), the implementation of test and treat across Zambia(34), entry HIV testing and treatment(6) and use of correctional health committees to strengthen TB/HIV service delivery at facility level(9). Among African countries with studies involving several correctional facilities, Zambia's prevalence is lower than South Africa's (25) but higher than Burkina Faso and Uganda.

The difference in prevalence of TB and HIV between residents and new entrants into correctional facilities was not statistically significant. This is possibly due to the following reasons: a) individuals entering correctional facilities come from socio-economically disadvantaged backgrounds where prevalence of TB and HIV are already high (1); b) there are high rates of recidivism (35); and c) detainees spend long periods in police cells, which have similar conditions to the correctional facilities (36, 37). However, the small sample size and wide confidence intervals especially for the new entrants is a limiting factor for drawing any inferences from this comparison. This finding highlights the contribution of imported TB and HIV cases to the burden of disease in correctional facilities and underscores the importance of entry screening within this setting.

## **308 Strengths and limitations**

This study provides the most recent evidence on prevalence of TB and HIV in Zambian correctional facilities. The results of this study are generalizable to the 13 correctional facilities, as a large sample representing 85% and 84% of the 13 correctional facility population, was screened for TB and HIV respectively. By virtue of the data being disaggregated, it provides an opportunity for targeting of interventions that can reduce the

#### **BMJ** Open

burden of both diseases. However, there were variations in the strength of screening algorithms for TB, hence the prevalence of TB could have been underestimated in some correctional facilities. That said, among all forms TB cases, it is possible that some of the clinically diagnosed TB cases might not be true TB cases as there are other differential causes of chest x-ray abnormalities that mimic TB. Inmates in court or on the farms were not screened for TB which could have introduced bias during data collection. Additionally, asymptomatic TB was not consistently screened for.

322 CONCLUSION

Despite significant progress over the last decade in controlling TB and HIV in Zambian correctional facilities, these continue to be disproportionately affected by both diseases. TB/HIV programs in correctional facilities need further strengthening to include aspects of juvenile specific TB programming, gender responsive HIV programming and holistic integrated service delivery as TB and HIV are not exclusive health concerns of incarcerated individuals. Additionally, there is need to consider use of more sensitive algorithms that include chest x-ray to minimize the risk of missing asymptomatic TB cases. Additional studies are required to determine the true prevalence of asymptomatic TB in correctional facilities, to better understand the reason for high HIV burden among females in correctional facilities and to determine the prevalence of TB and HIV using a sample whose results can be generalized to all the correctional facilities in Zambia.

 ETHICS STATEMENT

Approval to use the programmatic data was obtained from the University of Zambia Biomedical Research Ethics Committee No: 018-11-18 and the London School of Hygiene and Tropical Medicine Ethics Committee No: 21332. Since data was collected under programmatic conditions, no consent was sought for TB screening and verbal consent and assent were obtained for HIV testing. The EJJOH project had obtained permission from the Zambia Correctional service and the Ministry of Community Development and Social services to conduct the screening activities including testing of juveniles. When migrating data from the paper-based registers to the electronic database, participant identifying information was

excluded.

#### REFERENCES

World Health Organization. Tuberculosis in Prisons [cited 2020 20th July 2020]. Available 1. from: https://www.who.int/tb/areas-of-work/population-groups/prisons-facts/en/. Telisinghe L, Charalambous S, Topp SM, Herce ME, Hoffmann CJ, Barron P, et al. HIV and 2. tuberculosis in prisons in sub-Saharan Africa. The Lancet. 2016;388(10050):1215-27. 3. Dolan K, Wirtz AL, Moazen B, Ndeffo-Mbah M, Galvani A, Kinner SA, et al. Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees. The Lancet. 2016;388(10049):1089-102.

Reid SE, Topp SM, Turnbull ER, Hatwiinda S, Harris JB, Maggard KR, et al. Tuberculosis and 4. HIV control in sub-Saharan African prisons: "thinking outside the prison cell". Journal of Infectious Diseases. 2012;205(suppl\_2):S265-S73.

5. World Health Organization Regional Office for Europe. Prisons and health. Copenhagen, Denmark2014. 45-70, 83 p.

Maggard KR, Hatwiinda S, Harris JB, Phiri W, Krüüner A, Kaunda K, et al. Screening for 6. tuberculosis and testing for human immunodeficiency virus in Zambian prisons. Bulletin of the World Health Organization. 2015;93:93-101.

Ubumi Prisons Iniative. Zambian Prisons [updated 4th August 2020; cited 2020 4th August 7. 2020]. Available from: <u>https://ubumi.net/zambian\_prisons.html</u>.

8. Herce ME, Hoffmann CJ, Fielding K, Topp SM, Hausler H, Chimoyi L, et al. Universal test-and-treat in Zambian and South African correctional facilities: a multisite prospective cohort study. The Lancet HIV. 2020;7(12):e807-e16.

Topp SM, Sharma A, Moonga CN, Chileshe C, Magwende G, Henostroza G. Evaluation of a 9. health system strengthening initiative in the Zambian prison system. BMJ global health. 2018;3(1).

10. Herce ME, Muyoyeta M, Topp SM, Henostroza G, Reid SE. Coordinating the prevention, treatment, and care continuum for HIV-associated tuberculosis in prisons: a health systems strengthening approach. Current Opinion in HIV and AIDS. 2018;13(6):492. 11. Institute of Crime and Justice Policy Research B. World Prison Brief 2020 [cited 2020 21st July 2020]. Available from: https://www.prisonstudies.org/country/zambia. 12. Government of the Republic of Zambia. The Juvenile Act. Chapter 53 of the Laws of Zambia1964. 13. Government of the Republic of Zambia. The Prisons Act Lusaka, Zambia: Government Printer; 2004 [cited 2020 13th May 2020]. Available from: https://www.parliament.gov.zm/node/840. 14. Kapata N, Chanda-Kapata P, Ngosa W, Metitiri M, Klinkenberg E, Kalisvaart N, et al. The prevalence of tuberculosis in Zambia: results from the first national TB prevalence survey, 2013– 2014. PLoS One. 2016;11(1):e0146392. Kapata N, Mbulo G, Cobelens F, de Haas P, Schaap A, Mwamba P, et al. The second Zambian 15. national tuberculosis drug resistance survey-a comparison of conventional and molecular methods. Tropical Medicine & International Health. 2015;20(11):1492-500. 16. Ministry of Health Zambia. Zambia Population-based HIV Impact assessment 2016. Lusaka; 2019. 17. Donald PR, Marais BJ, Barry CE. Age and the epidemiology and pathogenesis of tuberculosis. The Lancet. 2010;375(9729):1852-4. Stop TB partnership. Tuberculosis Situation in 2019, Zambia [cited 2021 19th February 18. 2021]. Available from: http://stoptb.org/resources/cd/ZMB Dashboard.html. 19. Todrys KW, Amon JJ. Human rights and health among juvenile prisoners in Zambia. Int J Prison Health. 2011;7(1):10-7. 20. Mabud TS, de Lourdes Delgado Alves M, Ko AI, Basu S, Walter KS, Cohen T, et al. Evaluating strategies for control of tuberculosis in prisons and prevention of spillover into communities: An observational and modeling study from Brazil. PLoS medicine. 2019;16(1):e1002737. 21. World Health Organisation. Chest Radiography in Tuberculosis Case Detection. Switzerland2016 [cited 2021 10th June 2021]. Available from: https://apps.who.int/iris/bitstream/handle/10665/252424/9789241511506-eng.pdf;jsessionid=72EC9D02021FEBF4C6CCA41896818F45?sequence=1. 22. World Health Organisation. WHO operational handbook on TB diagnosis. Geneva2020 [cited 2021 1oth June 2021]. Available from: https://www.who.int/publications/i/item/who-operational-handbook-on-tuberculosis-module-3-diagnosis---rapid-diagnostics-for-tuberculosis-detection. 23. Melese A, Demelash H. The prevalence of tuberculosis among prisoners in Ethiopia: a systematic review and meta-analysis of published studies. Archives of Public Health. 2017;75(1):1-9. 24. Banda H, Gausi F, Harries A, Salaniponi F. Prevalence of smear-positive pulmonary tuberculosis among prisoners in Malawi: a national survey. The international journal of tuberculosis and lung disease. 2009;13(12):1557-9. 25. Stevenson KA, Podewils LJ, Zishiri VK, Castro KG, Charalambous S. HIV prevalence and the cascade of care in five South African correctional facilities. PLoS One. 2020;15(7):e0235178. 26. Organization WH. WHO policy on TB infection control in health-care facilities, congregate settings and households. World Health Organization; 2009. Report No.: 9241598328. 27. World health Organisation. Global Tuberculosis Report 2019 2019 [Available from: https://apps.who.int/iris/bitstream/handle/10665/329368/9789241565714-eng.pdf?ua=1. 28. Gizachew Beza M, Hunegnaw E, Tiruneh M. Prevalence and associated factors of tuberculosis in prisons settings of East Gojjam Zone, Northwest Ethiopia. International journal of bacteriology. 2017;2017. Séri B, Koffi A, Danel C, Ouassa T, Blehoué M-A, Ouattara E, et al. Prevalence of pulmonary 29. tuberculosis among prison inmates: A cross-sectional survey at the Correctional and Detention Facility of Abidjan, Côte d'Ivoire. PloS one. 2017;12(7):e0181995. 

BMJ Open


2		
3	418	30. Noeske J, Ndi N, Mbondi S. Controlling tuberculosis in prisons against confinement
4	419	conditions: a lost case? Experience from Cameroon. The International journal of tuberculosis and
5	420	lung disease. 2011;15(2):223-7.
6		•
7	421	31. United Nations Office on Drug and Crime U. Women and HIV in prison settings Austria2008
8	422	[cited 2021 1st February 2021]. Available from:
9	423	https://www.unodc.org/documents/middleeastandnorthafrica/drug-prevention-health-
10	424	publications/WOMEN_AND_HIV_IN_PRISON_SETTINGS.pdf.
11	425	32. Todrys KW, Amon JJ. Health and human rights of women imprisoned in Zambia. BMC
12	426	international health and human rights. 2011;11(1):1-7.
13	427	33. Simooya OO, Sanjobo NE, Kaetano L, Sijumbila G, Munkonze FH, Tailoka F, et al. 'Behind
14	428	walls': a study of HIV risk behaviours and seroprevalence in prisons in Zambia. Aids.
15	429	2001;15(13):1741-4.
16	430	34. Zambia MoH. Zambia Consolidated Guidelines on Treatment and Prevention of HIV
17		
18	431	infection. Lusaka; 2016.
19	432	35. Yukhnenko D, Sridhar S, Fazel S. A systematic review of criminal recidivism rates worldwide:
20	433	3-year update. Wellcome open research. 2019;4.
21	434	36. Henostroza G, Topp SM, Hatwiinda S, Maggard KR, Phiri W, Harris JB, et al. The high burden
22	435	of tuberculosis (TB) and human immunodeficiency virus (HIV) in a large Zambian prison: a public
23	436	health alert. PloS one. 2013;8(8):e67338.
24	437	37. Todrys KW, Amon JJ, Malembeka G, Clayton M. Imprisoned and imperiled: access to HIV and
25 26	438	TB prevention and treatment, and denial of human rights, in Zambian prisons. Journal of the
26 27	439	International AIDS Society. 2011;14(1):1-11.
27	137	
28 29	440	
30		
31		
32	441	
33		
34		
35		
36	442	The Zambia Correctional Service, Ministry of Community Development and Social Welfare and
37		
38	443	the correctional health committees are acknowledged for the support provided to the EJJOH
39		
40		and the first of the state of t
41	444	project team during data collection. Innocent Mwaba is acknowledged for drawing the map
42		
43	445	showing study sites.
44		
45	446	
46	440	
47		
48		
49	447	FUNDING
50	44 /	
51		
52		
53	448	This research was funded by the Elton John AIDS Foundation; under the Elton John Juveniles
54		
55	440	Offenders' Health (FUOII) project (as great as when reaches i)
56	449	Offenders' Health (EJJOH) project (no grant number received).
57		
58 50	450	
59 60		
60		

2	
3	
4	
5	
6	
7	
/	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
10	
10	
<ol> <li>11</li> <li>12</li> <li>13</li> <li>14</li> <li>15</li> <li>16</li> <li>17</li> <li>18</li> <li>19</li> <li>20</li> </ol>	
20	
21	
22	
23	
24 25	
25	
26	
27	
28	
20	
29	
30	
31	
32	
33	
34	
35	
36	
36 37	
38	
29	
40	
41	
42	
43	
44	
45	
46	
47	
48	
40 49	
49 50	
51	
52	
53	
54	
55	
56	
57	
58	
58 59	
79	

60

# 451 AUTHOR CONTRIBUTIONS


452 Conceived and designed the study: MK, SH, CNM, MM. Database design and data curation: 453 PS, JB. Implemented the study: MK, SH, MT, TZ, CNM, MM. Data analysis: PS, MK, FB. Wrote 454 the original draft: MK. Reviewed the manuscript: SH, MT, JB, PS, TZ, FB, CNM, MM. Approved 455 the final version to be published: MK, SH, PS, MT, JB, TZ, FB, CNM, MM. 456 The corresponding author attests that all listed authors meet authorship criteria and that no 457 others meeting the criteria have been omitted. 458 CONFLICT OF INTEREST 459 460 The authors declare no conflict of interest. 461 DATA SHARING STATEMENT 462 463 Additional data is available upon request by emailing Monde.Muyoyeta@cidrz.org



HIV- Human Immunodeficiency Virus, TB- Tuberculosis

 \*All symptomatic patients submitted sputum, however, some correctional facilities only documented results of patients with positive results.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml



1
2
3
4
5 6
-
/ 8
8 9
9 10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32 33
33 34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54 57
55 56
56 57
57 58
58 59
59 60

STROBE Statement—Checklist of items that should be included in	reports of cross-sectional studies

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or	1
		the abstract	
		(b) Provide in the abstract an informative and balanced summary of what	2,3
		was done and what was found	
Introduction			1
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5,6
Objectives	3	State specific objectives, including any prespecified hypotheses	6
Methods			
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of	6,7
betting	2	recruitment, exposure, follow-up, and data collection	0,7
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection	7,8
Participants	0	of participants	/,0
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders,	8,9
	/	and effect modifiers. Give diagnostic criteria, if applicable	0,7
Data sources/	8*	For each variable of interest, give sources of data and details of methods	7,8
Data sources/ measurement	0.	of assessment (measurement). Describe comparability of assessment	/,0
		methods if there is more than one group	
Bias	9		7
		Describe any efforts to address potential sources of bias	
Study size	10	Explain how the study size was arrived at	7
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If	8,9
	10	applicable, describe which groupings were chosen and why	0.0
Statistical methods	12	( <i>a</i> ) Describe all statistical methods, including those used to control for confounding	8,9
		(b) Describe any methods used to examine subgroups and interactions	8,9
		(c) Explain how missing data were addressed	9
		(d) If applicable, describe analytical methods taking account of sampling	
		strategy	
		( <u>e</u> ) Describe any sensitivity analyses	
Results			·
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers	9, 10
		potentially eligible, examined for eligibility, confirmed eligible, included	,
		in the study, completing follow-up, and analysed	
		(b) Give reasons for non-participation at each stage	9,10
		(c) Consider use of a flow diagram	10
Descriptive data Outcome data	14*	(a) Give characteristics of study participants (eg demographic, clinical,	10,11
	14	social) and information on exposures and potential confounders	10,11
		(b) Indicate number of participants with missing data for each variable of	11-
		interest	14
	15*	Report numbers of outcome events or summary measures	14

Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted	
		estimates and their precision (eg, 95% confidence interval). Make clear	
		which confounders were adjusted for and why they were included	
		(b) Report category boundaries when continuous variables were	11
		categorized	14
		(c) If relevant, consider translating estimates of relative risk into absolute	
		risk for a meaningful time period	
Other analyses	17	Report other analyses done-eg analyses of subgroups and interactions,	11
		and sensitivity analyses	14
Discussion			
Key results	18	Summarise key results with reference to study objectives	14
Limitations	19	Discuss limitations of the study, taking into account sources of potential	17
		bias or imprecision. Discuss both direction and magnitude of any potential	18
		bias	
Interpretation	20	Give a cautious overall interpretation of results considering objectives,	14
		limitations, multiplicity of analyses, results from similar studies, and other	17
		relevant evidence	
Generalisability	21	Discuss the generalisability (external validity) of the study results	17
Other information			
Funding	22	Give the source of funding and the role of the funders for the present	21
		study and, if applicable, for the original study on which the present article	
		is based	

\*Give information separately for exposed and unexposed groups.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.